1
|
Hurvitz S, Kalinsky K, Tripathy D, Sledge G, Gradishar W, O'Shaughnessy J, Modi S, Park H, McCartney A, Frentzas S, Shannon C, Cuff K, Eek R, Martin Jimenez M, Curigliano G, Jerusalem G, Huang C, Press M, Lu J. 273TiP ACE-Breast-03: A phase II study patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens treated with ARX788. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
2
|
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31:1623-1649. [PMID: 32979513 PMCID: PMC7510449 DOI: 10.1016/j.annonc.2020.09.010] [Citation(s) in RCA: 669] [Impact Index Per Article: 167.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 09/15/2020] [Accepted: 09/16/2020] [Indexed: 01/09/2023] Open
Affiliation(s)
- F Cardoso
- Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
| | - S Paluch-Shimon
- Sharett Division of Oncology, Hadassah University Hospital, Jerusalem, Israel
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - G Curigliano
- Department of Oncology and Hemato-Oncology, European Institute of Oncology, IRCCS, Division of Early Drug Development, University of Milan, Milan, Italy
| | - M S Aapro
- Breast Center, Clinique de Genolier, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - C H Barrios
- Latin American Cooperative Oncology Group (LACOG), Grupo Oncoclínicas, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden
| | - G S Bhattacharyya
- Department of Medical Oncology, Salt Lake City Medical Centre, Kolkata, India
| | - L Biganzoli
- Department of Medical Oncology, Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy
| | - F Boyle
- The Pam McLean Centre, Royal North Shore Hospital, St Leonards, Australia
| | - M-J Cardoso
- Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Nova Medical School, Lisbon, Portugal
| | - L A Carey
- Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
| | - J Cortés
- IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain; Department of Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - N S El Saghir
- Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - M Elzayat
- Europa Donna, The European Breast Cancer Coalition, Milan, Italy
| | - A Eniu
- Interdisciplinary Oncology Service (SIC), Riviera-Chablais Hospital, Rennaz, Switzerland
| | - L Fallowfield
- SHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK
| | - P A Francis
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- Medical Oncology Department, BC Cancer Agency, Vancouver, Canada
| | - J Gligorov
- Breast Cancer Expert Center, University Cancer Institute APHP, Sorbonne University, Paris, France
| | - R Haidinger
- Brustkrebs Deutschland e.V., Munich, Germany
| | - N Harbeck
- Breast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany
| | - X Hu
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - B Kaufman
- Department of Oncology, Sheba Medical Center, Ramat Gan, Israel
| | - R Kaur
- Breast Cancer Welfare Association Malaysia, Petaling Jaya, Malaysia
| | - B E Kiely
- NHMRC Clinical Trials Centre, Sydney Medical School, Sydney, Australia
| | - S-B Kim
- Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea
| | - N U Lin
- Susan Smith Center for Women's Cancers - Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA
| | - S A Mertz
- Metastatic Breast Cancer Network, Inverness, USA
| | - S Neciosup
- Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, Peru
| | - B V Offersen
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - S Ohno
- Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan
| | - O Pagani
- Medical School, Geneva University Hospital, Geneva, Switzerland
| | - A Prat
- Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona; Department of Medicine, University of Barcelona, Barcelona
| | - F Penault-Llorca
- Department of Biopathology, Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne/INSERM U1240, Clermont-Ferrand, France
| | - H S Rugo
- Breast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - G W Sledge
- Division of Oncology, Stanford School of Medicine, Stanford, USA
| | - C Thomssen
- Department of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany
| | - D A Vorobiof
- Oncology Research Unit, Belong.Life, Tel Aviv, Israel
| | - T Wiseman
- Department of Applied Health Research in Cancer Care, The Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - B Xu
- Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
| | - L Norton
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - A Costa
- European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
| | - E P Winer
- Susan Smith Center for Women's Cancers - Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
3
|
Huang CS, Toi M, Im YH, Iwata H, Sohn J, Wang HC, Masuda N, Im SA, Lu Y, Haddad N, Sakaguchi S, Hurt K, Neven P, Llombart-Cussac A, Sledge G. 45O Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
4
|
Rosenberg SM, O'Neill A, Sepucha K, Miller KD, Dang CT, Northfelt DW, Sledge GW, Schneider BP, Partridge AH. Abstract GS6-05: The impact of breast cancer surgery on quality of life: Long term results from E5103. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs6-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer (BC) treatment, including surgery, can impact not only short-term health outcomes but may also affect longer term health-related and psychosocial quality of life (QOL). We sought to describe the impact of BC surgery on QOL among breast cancer survivors followed in a large randomized trial.
Methods: The ECOG-ACRIN protocol E5103 was a phase III trial that randomized BC patients (pts) who had undergone definitive BC surgery to receive adjuvant doxorubicin, cyclophosphamide, and paclitaxel with either bevacizumab (bev) or placebo. Telephone based surveys were administered to all pts enrolled between 01/Jan/10 and 08/Jun/10 as part of a Decision-Making/QOL component until 18 mos post enrollment. Functional/psychosocial QOL domains were assessed by the EQ-5D-3L and the FACT B+G. Fisher's exact test compared categorical and Wilcoxon rank sum test compared continuous variables between subgroups. Multivariable regression was used to evaluate factors in addition to primary surgery at enrollment (age, race, ER/PgR status, tumor size, nodal status) associated with overall FACT score at 18 mos.
Results: Patient reported outcomes at 18 mos were available from 89.6% (465/519) pts. At enrollment, 57% (266/465) had a mastectomy; 43% (199/465) breast conserving surgery (BCS). Median age at enrollment was 52 (range: 25-76) years. There were no differences in QOL between bev vs placebo treatment arms (EQ-5D-3L Index Score p=0.65; FACT B+G Score p=0.23) at 18 mos so groups were combined. Using EQ-5D-3L, over half of the pts (58%) reported at least some pain/discomfort; 38% symptoms of anxiety/depression. A higher proportion of mastectomy pts reported problems with usual activities compared to BCS pts (Table). Compared to BCS pts, mastectomy pts had lower average EQ5D-3L scores 0.80 vs. 0.84, p=0.04 and FACT B+G scores 109 vs. 114, p=0.01, indicating worse QOL. In univariate analyses, non-white race (p=0.03), ER/PgR+ status (p=0.04) and mastectomy as primary surgery (p=0.01) were significantly associated with worse QOL (lower FACT B+G scores). In multivariable analyses, non-white race (p=0.02) and ER/PgR+ status (p=0.05) remained associated with worse QOL; mastectomy was borderline significant (p=0.06).
Conclusions: Among women participating in a contemporary adjuvant BC chemotherapy trial, a substantial proportion of survivors experience symptoms that may be amenable to intervention, including referral to physical rehabilitation, especially among pts undergoing more extensive surgery. Attention to psychosocial health is also essential both during and after completion of active treatment to optimize QOL outcomes.
N(%) reporting problems* 5 DimensionsBCSMastectomyOverallp**Mobility44(23)59(23)103(23)1.00Self-care11(6)23(9)34(7)0.21Usual activities49(25)90(34)139(30)0.04Pain/discomfort104(53)161(61)265(58)0.08Anxiety/depression70(36)105(40)175(38)0.44*3L: 3 possible answers: 1) no problems 2) some/moderate problems 3) problems; responses then collapsed into no problems vs. any problems' (=some/moderate problems and problems). ** Fisher's exact test p-value.
Citation Format: Rosenberg SM, O'Neill A, Sepucha K, Miller KD, Dang CT, Northfelt DW, Sledge GW, Schneider BP, Partridge AH. The impact of breast cancer surgery on quality of life: Long term results from E5103 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS6-05.
Collapse
Affiliation(s)
- SM Rosenberg
- Dana-Farber Cancer Institute, Boston, MA; ECOG-ACRIN Biostatistics Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA
| | - A O'Neill
- Dana-Farber Cancer Institute, Boston, MA; ECOG-ACRIN Biostatistics Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA
| | - K Sepucha
- Dana-Farber Cancer Institute, Boston, MA; ECOG-ACRIN Biostatistics Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA
| | - KD Miller
- Dana-Farber Cancer Institute, Boston, MA; ECOG-ACRIN Biostatistics Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA
| | - CT Dang
- Dana-Farber Cancer Institute, Boston, MA; ECOG-ACRIN Biostatistics Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA
| | - DW Northfelt
- Dana-Farber Cancer Institute, Boston, MA; ECOG-ACRIN Biostatistics Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA
| | - GW Sledge
- Dana-Farber Cancer Institute, Boston, MA; ECOG-ACRIN Biostatistics Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA
| | - BP Schneider
- Dana-Farber Cancer Institute, Boston, MA; ECOG-ACRIN Biostatistics Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA
| | - AH Partridge
- Dana-Farber Cancer Institute, Boston, MA; ECOG-ACRIN Biostatistics Center, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University, Indianapolis, IN; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Rochester, MN; Stanford University, Stanford, CA
| |
Collapse
|
5
|
Wagner LI, Gray RJ, Garcia S, Whelan TJ, Tevarweerk A, Yanez B, Carlos R, Gareen I, McCaskill-Stevens W, Cella D, Sparano JA, Sledge GW. Abstract GS6-03: Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs6-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: TAILORx patient-reported outcomes (PRO) quantify symptoms and health-related quality of life (HRQL) from C+E beyond E alone from the patient's perspective, thus can inform decision-making for women in the intermediate risk group for whom chemotherapy may still be considered.
Methods: TAILORx participants with OncoType DX Recurrence Scores 11-25 were randomly assigned to E or C+E. All TAILORx participants enrolled 1/2010-10/2010 (N=612) completed PROs measuring fatigue, endocrine symptoms, cognitive impairments (PCI), and fear of recurrence at baseline, 3, 6, 12, 24 and 36 months. HRQL was assessed at baseline, 12, and 36 months. Linear regression (LR) examined PRO scores among the per-protocol sample.
Results: Overall, participants reported significantly more fatigue, endocrine symptoms and PCI at 3, 6, 12, 24 and 36 months compared to baseline and those randomized to C+E reported a greater magnitude of change baseline-3 months compared to those randomized to E alone (Table 1). Overall, by 12 months symptoms were comparable between groups. Pre-menopausal women had comparable symptoms at 24 and 36 months. Post-menopausal women randomized to C+E had greater endocrine symptoms at 24 and 36 months and greater fatigue at 6 and 24 months. Fear of recurrence was comparable between arms during treatment and follow-up. Multiple linear regression identified increased fatigue (LR slope β=0.67), endocrine symptoms (β =0.14), and PCI (β=0.11) as significant predictors of decreased HRQL across arms (p< 0.001). HRQL was comparable between E and C+E at 12- and 36-months.
Mean PRO change scores from baseline by treatment arm and menopausal status in per protocol population Months 36122436N=Overall454469458384343n=Pre-menopausal153151150118103n=Post-menopausal301318308266240FACIT-Fatigue Overall sample C+E-8.77-4.37-4.01-4.27-3.67E-2.48-1.97-2.14-1.49-1.83LMED-5.32***-1.55-1.01-1.76-0.90Pre-M C+E-8.01-3.26-2.99-2.45-1.60E-3.87-1.66-1.32-2.52-2.11LMED-3.11-0.82-1.121.021.46Post-M C+E-9.22-4.97-4.55-5.14-4.67E-1.87-2.10-2.52-1.09-1.71LMED-6.42***-1.99*-1.16-3.02*-2.01FACT-Endocrine Symptoms Overall sample C+E-5.56-5.63-6.96-6.81-7.14E-3.61-4.24-5.62-5.31-5.17LMED-1.62*-0.97-1.08-1.05-1.69Pre-M C+E-7.62-8.34-7.94-8.29-8.96E-5.96-6.19-8.95-10.39-10.84LMED-1.44-1.631.062.272.18Post-M C+E-4.39-4.19-6.45-6.10-6.28E-2.55-3.41-4.10-3.23-2.87LMED-1.49-0.45-2.04-2.39*-3.17**Significance between mean change scores *p<0.05;**p<0.01;***p<0.001. LMED=estimated tx difference using linear model regressing score on baseline value and tx
Conclusions: TAILORx is the first trial to examine patient-reported fatigue, endocrine symptoms, PCI and HRQL among breast cancer patients randomized to endocrine therapy alone vs chemoendocrine therapy, thus allowing us to quantify acute and long-term symptoms uniquely attributable to chemotherapy. As expected, chemotherapy is associated with greater fatigue, endocrine symptoms and PCI acutely during treatment, and for post-menopausal women with greater long-term endocrine symptoms. Increased symptoms were associated with poorer HRQL. Long-term HRQL was comparable between groups.
Citation Format: Wagner LI, Gray RJ, Garcia S, Whelan TJ, Tevarweerk A, Yanez B, Carlos R, Gareen I, McCaskill-Stevens W, Cella D, Sparano JA, Sledge, Jr. GW, On behalf of the TAILORx Study Team. Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS6-03.
Collapse
Affiliation(s)
- LI Wagner
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | - RJ Gray
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | - S Garcia
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | - TJ Whelan
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | - A Tevarweerk
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | - B Yanez
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | - R Carlos
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | - I Gareen
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | - W McCaskill-Stevens
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | - D Cella
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | - JA Sparano
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | - GW Sledge
- Wake Forest School of Medicine, Winston Salem, NC; Dana-Farber Cancer Institute, Boston, MA; Northwestern University School of Medicine, Chicago, IL; McMaster University, Hamilton, ON, Canada; University of Wisconsin, Madison, WI; University of Michigan, Ann Arbor, MI; Brown University, Providence, RI; National Institutes of Health, National Cancer Institute, Bethesda, MD; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Stanford University Medical Center, Stanford, CA
| | | |
Collapse
|
6
|
Albain K, Gray RJ, Sparano JA, Makower DF, Pritchard KI, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs4-07] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Black race is associated with worse outcomes in localized hormone receptor (HR)-positive breast cancer in population-based and in clinical trial cohorts, whether using self-identified race (Albain et al. JNCI 2009 [PMID: 19584328; Sparano et al. JNCI 2012 [PMID: 22250182) or genetically-identified race (Schneider et al. J Precision Oncol 2017 [PMID: 29333527]). This disparity persists after adjustment for treatment delivery parameters (Hershman et al. JCO 2009 [PMID:19307504]). We evaluated clinicopathologic characteristics, treatment delivered and clinical outcomes in the Trial Assigning Individualized Options for Treatment (TAILORx) by race and ethnicity (Sparano et al. NEJM 2018 [PMID: 29860917]).
Methods: The analysis included 9719 evaluable TAILORx participants. The association between clinical outcomes and race (white, black, Asian, other/unknown) and ethnicity (Hispanic vs. non-Hispanic) was examined, including invasive disease-free survival (iDFS), distant relapse-free interval (DRFI), relapse-free interval (RFI), and overall survival (OS). Proportional hazards models were fit including age (5 categories), tumor size (>2 cm vs. <=2 cm), histologic grade (high vs. medium vs. low vs. unknown), continuous recurrence score (RS), race, and ethnicity in the overall population and randomized treatment arms in the RS 11-25 cohort.
Results: The study population included 8189 (84%) whites, 693 (7%) blacks, 405 (4%) Asians, and 432 (4%) with other/unknown race. Regarding ethnicity, 7635 (79%) were non-Hispanic, 889 (9%) Hispanic, and 1195 (12%) unknown. There was no significant difference in RS distribution (p=0.22) in blacks compared with whites, or in median (17 vs. 17) or mean RS (19.1 vs. 18.2). There was likewise no difference in Hispanic vs. non-Hispanic ethnicity for RS distribution (p=0.72) or median (17 vs. 17) or mean RS (18.5 vs. 18.0). Black race (39% vs. 30%) and Hispanic ethnicity (39% vs. 30%) were both associated with younger age (</=50 years) at diagnosis. The use and type of adjuvant chemotherapy and endocrine therapy, and duration of endocrine therapy, were similar in black (vs. white) and Hispanic (vs. non-Hispanic) populations. In proportional hazards models, black race (compared with white race) was associated with worse clinical outcomes in the entire population and in those with a RS 11-25 (see table). Hispanic ethnicity was generally associated with better outcomes (compared with non-Hispanic ethnicity). For the cohort with a RS of 11-25, there was no evidence for chemotherapy benefit for any racial or ethnic group.
Race (black vs.white) and clinical outcomes in proportional hazards modelsClinical endpointEntire Population (N=693 black) Hazard ratio for eventRS 11-25 (N=471 black) Hazard ratio for eveniDFS1.33 (p=0.005)1.49 (p=0.001)DRFI1.21 (p=0.28)1.60 (p=0.02)RFI1.39 (p=0.02)1.80 (p<0.001)OS1.52 (p=0.005)1.67 (p=0.003
Conclusions: In patients eligible and selected for participation in TAILORx, black women had worse clinical outcomes despite similar 21-gene assay RS results and comparable systemic therapy. This adds to an emerging body of evidence suggesting a biologic basis or other factors contributing to racial disparities in HR-positive breast cancer that requires further evaluation.
Citation Format: Albain K, Gray RJ, Sparano JA, Makower DF, Pritchard KI, Hayes DF, Geyer, Jr. CE, Dees EC, Goetz MP, Olson, Jr. JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge, Jr. GW. Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS4-07.
Collapse
Affiliation(s)
- K Albain
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - RJ Gray
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - JA Sparano
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - DF Makower
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - KI Pritchard
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - DF Hayes
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - CE Geyer
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - EC Dees
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - MP Goetz
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - JA Olson
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - T Lively
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - SS Badve
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - TJ Saphner
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - LI Wagner
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - TJ Whelan
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - MJ Ellis
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - S Paik
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - WC Wood
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - PM Ravdin
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - MM Keane
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - HL Gomez
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - PS Reddy
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - TF Goggins
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - IA Mayer
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - AM Brufsky
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - DL Toppmeyer
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - VG Kaklamani
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - JL Berenberg
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - J Abrams
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| | - GW Sledge
- Loyola University Chicago Stritch School of Medicine, Maywood, IL; Dana Farber Cancer Institute, Boston, MA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Sunnybrook Research Institute, Toronto, Canada; University of Michigan, Ann Arbor, MI; Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond, VA; University of North Carolina, Chapel Hill, NC; Mayo Clinic, Rochester, MN; University of Maryland School of Medicine, Baltimore, MD; National Institutes of Health, National Cancer Institute, Bethesda, MD; Indiana University School of Medicine, Indianapolis, IN; Vince Lombardi Cancer Clinic, Two Rivers, WI; Wake Forest University Health Service, Winston Salem, NC; McMaster University, Hamilton, Canada; Baylor College of Medicine, Houston, TX; Yonsei University College of Medicine, Seoul, South Korea; Emory University, Atlanta, GA; , San Antonio, TX; Cancer Trials Ireland, Dublin, Ireland; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; C
| |
Collapse
|
7
|
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol 2018; 29:1634-1657. [PMID: 30032243 PMCID: PMC7360146 DOI: 10.1093/annonc/mdy192] [Citation(s) in RCA: 761] [Impact Index Per Article: 126.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology (ESO), European Society for Medical Oncology (ESMO) and Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
| | - E Senkus
- European Society for Medical Oncology (ESMO) and Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - A Costa
- European School of Oncology, Milan, Italy
| | | | - M Aapro
- Oncology Department, Clinique de Genolier, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - N Harbeck
- Breast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany
| | - B Aguilar Lopez
- Direction Office, ULACCAM (Union Latinoamericana Contra el Cáncer de la Mujer), Mexico DF, Mexico
| | - C H Barrios
- Department of Oncology, PURCS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden
| | - L Biganzoli
- European Society of Breast Cancer Specialists (EUSOMA) and Department of Medical Oncology, Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy
| | | | - M J Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation and Nova Medical School, Lisbon, Portugal
| | - L A Carey
- Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
| | - J Cortés
- Department of Oncology, Vall d' Hebron University, Barcelona, Spain
| | - G Curigliano
- Division of Early Drug Development, Department of Oncology and Hemato-Oncology, European Institute of Oncology, University of Milano, Milano, Italy
| | - V Diéras
- Gynaecology and Breast Department, Centre Eugène Marquis, Rennes, France
| | - N S El Saghir
- Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - A Eniu
- Breast Cancer Department, Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania
| | - L Fallowfield
- SHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK
| | - P A Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- Medical Oncology Department, BC Cancer Agency, Vancouver, Canada
| | | | - B Kaufman
- Department of Oncology, Sheba Medical Center, Ramat Gan, Israel
| | - S Koppikar
- Department of Medical Oncology, Bombay Hospital Institute of Medical Sciences, Mumbai, India
| | - I E Krop
- Breast Oncology Center Dana-Farber Cancer Institute, Boston, USA
| | - M Mayer
- Advanced BC.org, New York, USA
| | - G Nakigudde
- Advocacy Department, UWOCASO (Uganda Women's Cancer Support Organization), Kampala, Uganda
| | - B V Offersen
- European Society of Radiation Oncology (ESTRO) and Department of Experimental Clinical Oncology & Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - S Ohno
- Cancer Institute Hospital, Breast Oncology Centre, Tokyo, Japan
| | - O Pagani
- Institute of Oncology of Southern Switzerland, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), International Breast Cancer Study Group (IBCSG), Bellinzona, Switzerland
| | - S Paluch-Shimon
- Oncology Institute, Shaare Zedek Medical Centre, Jerusalem, Israel
| | - F Penault-Llorca
- Department of Pathology, Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - A Prat
- IDIBAPS (Institut d'Investigacions Biomèdiques August Pi iSunyer), Hospital Clínic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumor, Barcelona, Spain
| | - H S Rugo
- Breast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - G W Sledge
- Oncology Division, Stanford University Medical Center, Stanford, USA
| | - D Spence
- Policy Department, Breast Cancer Network Australia, Camberwell, VIC, Australia
| | - C Thomssen
- Department of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany
| | - D A Vorobiof
- Oncology Department, Sandton Oncology Centre, Johannesburg, South Africa
| | - B Xu
- Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
| | - L Norton
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York
| | - E P Winer
- Dana-Farber Cancer Institute, Susan Smith Center for Women's Cancers, Breast Oncology Center, Boston, USA
| |
Collapse
|
8
|
Telli ML, Stover DG, Loi S, Aparicio S, Carey LA, Domchek SM, Newman L, Sledge GW, Winer EP. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Res Treat 2018; 171:21-31. [PMID: 29736741 DOI: 10.1007/s10549-018-4807-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Accepted: 04/30/2018] [Indexed: 12/21/2022]
Abstract
PURPOSE Triple-negative breast cancer (TNBC) is associated with worse outcomes relative to other breast cancer subtypes. Chemotherapy remains the standard-of-care systemic therapy for patients with localized or metastatic disease, with few biomarkers to guide benefit. METHODS We will discuss recent advances in our understanding of two key biological processes in TNBC, homologous recombination (HR) DNA repair deficiency and host anti-tumor immunity, and their intersection. RESULTS Recent advances in our understanding of homologous recombination (HR) deficiency, including FDA approval of PARP inhibitor olaparib for BRCA1 or BRCA2 mutation carriers, and host anti-tumor immunity in TNBC offer potential for new and biomarker-driven approaches to treat TNBC. Assays interrogating HR DNA repair capacity may guide treatment with agents inducing or targeting DNA damage repair. Tumor infiltrating lymphocytes (TILs) are associated with improved prognosis in TNBC and recent efforts to characterize infiltrating immune cell subsets and activate host anti-tumor immunity offer promise, yet challenges remain particularly in tumors lacking pre-existing immune infiltrates. Advances in these fields provide potential biomarkers to stratify patients with TNBC and guide therapy: induction of DNA damage in HR-deficient tumors and activation of existing or recruitment of host anti-tumor immune cells. Importantly, these advances provide an opportunity to guide use of existing therapies and development of novel therapies for TNBC. Efforts to combine therapies that exploit HR deficiency to enhance the activity of immune-directed therapies offer promise. CONCLUSIONS HR deficiency remains an important biomarker target and potentially effective adjunct to enhance immunogenicity of 'immune cold' TNBCs.
Collapse
Affiliation(s)
- M L Telli
- Stanford University School of Medicine, Stanford, CA, USA
| | - D G Stover
- Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. .,Ohio State University Comprehensive Cancer Center, Biomedical Research Tower, Room 512, 460 West 12th Ave, Columbus, OH, 43210, USA.
| | - S Loi
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - S Aparicio
- University of British Columbia, Vancouver, BC, Canada
| | - L A Carey
- University of North Carolina, Chapel Hill, NC, USA
| | - S M Domchek
- University of Pennsylvania School of Medicine, Philadelphia, PA, USA
| | - L Newman
- Henry Ford Hospital, Detroit, MI, USA
| | - G W Sledge
- Stanford University School of Medicine, Stanford, CA, USA
| | - E P Winer
- Dana Farber Cancer Institute, Boston, MA, USA
| |
Collapse
|
9
|
Di Leo A, Dickler M, Sledge GW, Toi M, Forrester T, Nanda S, Koustenis A, Bourayou N, Johnston S. Abstract P5-21-02: Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-21-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Abemaciclib is an oral, selective inhibitor of cyclin-dependent kinases 4 & 6 that is dosed on a twice daily continuous schedule. In patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC), abemaciclib has demonstrated clinical efficacy with a tolerable safety profile when administered as monotherapy in MONARCH 1 (NCT02102490), in combination with fulvestrant in MONARCH 2 (NCT02107703), and in combination with non-steroidal aromatase inhibitors (NSAI) in MONARCH 3 (NCT02246621). Inducing tumor response and delaying disease progression is of critical need in pts with liver metastases (mets).
Methods:
An exploratory subgroup analysis was conducted in pts with liver mets at baseline across the MONARCH 1, 2, and 3 studies. All pts had HR+, HER2- ABC. The primary endpoint of MONARCH 1 was objective response rate (ORR), and the primary endpoint of MONARCH 2 and 3 was investigator-assessed progression-free survival (PFS). Analysis methods for these endpoints were previously described. Key enrollment criteria and dosing information are listed in Table 1.
Table 1. Eligibility criteria and dosing information for the MONARCH 1, 2, and 3 studiesKey enrollment criteriaMONARCH 1MONARCH 2MONARCH 3Prior endocrine therapyProgressed on or after ETProgressed while receiving adjuvant or first-line ET, or ≤ 12 months from the end of adjuvant ETET naïve or disease relapse >12 months after (neo)adjuvant ETChemotherapy regimens in advanced setting1 or 200Visceral crisisNo restrictionNot permittedNot permittedDose and Schedule abemaciclib200 mg, twice daily, continuous150 mg1, twice daily, continuous150 mg, twice daily, continuousfulvestrant-500 mg, per label-anastrozole2--1 mg, dailyletrozole2--2.5 mg, daily1post-amendment; 2physician's choice of NSAI (anastrozole or letrozole); ET: endocrine therapy
Results:
Efficacy results of pts with liver mets are described in Table 2. The most frequent adverse events observed in pts with liver mets in MONARCH 1 were diarrhea, nausea, and fatigue and in the abemaciclib arms of MONARCH 2 and 3 were diarrhea, neutropenia, and nausea.
Table 2. PFS and response rates of pts with liver mets in MONARCH 1, 2, and 3 MONARCH 1MONARCH 2 abemaciclib armMONARCH 2 placebo armMONARCH 3 abemaciclib armMONARCH 3 placebo armPts with liver mets, n93115594830PFS, HR (95% CI)N/A.45 (.31, .64).47 (.25, .87)Median PFS, months5.611.63.115.07.2ORR, n (%)20 (21.5)54 (47.0)9 (15.3)26 (54.2)6 (20.0)CBR, n (%)39 (41.9)77 (67.0)21 (35.6)32 (66.7)12 (40.0)CBR: clinical benefit rate (complete response [CR] + partial response [PR] + stable disease ≥6 months); HR: hazard ratio; ORR: objective response rate (CR+PR); PFS: progression-free survival; pts: patients
Conclusions:
The results suggest that the combination of abemaciclib and endocrine therapy was an effective treatment option in pts with liver metastases, a population deriving modest benefit from single-agent endocrine therapy. Tolerability results were generally consistent with the safety populations previously reported for each study.
Citation Format: Di Leo A, Dickler M, Sledge GW, Toi M, Forrester T, Nanda S, Koustenis A, Bourayou N, Johnston S. Efficacy and safety of abemaciclib in patients with liver metastases in the MONARCH 1, 2, and 3 studies [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-21-02.
Collapse
Affiliation(s)
- A Di Leo
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Dickler
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - GW Sledge
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - M Toi
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - T Forrester
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Nanda
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - A Koustenis
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - N Bourayou
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - S Johnston
- Nuovo Ospedale di Prato S. Stefano – Istituto Toscano Tumori, Prato, Italy; Memorial Sloan Kettering Cancer Center, New York, NY; Stanford University School of Medicine, Stanford, CA; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Eli Lilly and Company, Indianapolis, IN; Eli Lilly and Company, Paris, France; The Royal Marsden NHS Foundation Trust, London, United Kingdom
| |
Collapse
|
10
|
Cardoso F, Harbeck N, Barrios CH, Bergh J, Cortés J, El Saghir N, Francis PA, Hudis CA, Ohno S, Partridge AH, Sledge GW, Smith IE, Gelmon KA. Research needs in breast cancer. Ann Oncol 2017; 28:208-217. [PMID: 27831505 DOI: 10.1093/annonc/mdw571] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
New research questions emerge as medical needs continue to evolve and as we improve our understanding of cancer biology and treatment of malignancies. Although significant advances have been made in some areas of breast cancer research resulting in improvements in therapies and outcomes over the last few decades, other areas have not benefited to the same degree and we continue to have many gaps in our knowledge. This article summarizes the 12 short and medium-term clinical research needs in breast cancer deemed as priorities in 2016 by a panel of experts, in an attempt to focus and accelerate future research in the most needed areas: (i) de-escalate breast cancer therapies in early breast cancer without sacrificing outcomes; (ii) explore optimal adjuvant treatment durations; (iii) develop better tools and strategies to identify patients with genetic predisposition; (iv) improve care in young patients with breast cancer; (v) develop tools to speed up drug development in biomarker-defined populations; (vi) identify and validate targets that mediate resistance to chemotherapy, endocrine therapy and anti-HER2 therapies; (vii) evaluate the efficacy of local-regional treatments for metastatic disease; (viii) better define the optimal sequence of treatments in the metastatic setting; (ix) evaluate the clinical impact of intra-patient heterogeneity (intra-tumor, inter-tumor and inter-lesion heterogeneity); (x) better understand the biology and identify new targets in triple-negative breast cancer; (xi) better understand immune surveillance in breast cancer and further develop immunotherapies; and (xii) increase survivorship research efforts including supportive care and quality of life.
Collapse
Affiliation(s)
- F Cardoso
- Breast Unit, Champalimaud Clinical Centre, Lisbon, Portugal
| | - N Harbeck
- Breast Center, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany
| | - C H Barrios
- School of Medicine, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology and Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden
| | - J Cortés
- Breast Cancer Unit, Ramon y Cajal University Hospital, Madrid.,Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - N El Saghir
- Department of Internal Medicine, NK Basile Cancer Institute American University of Beirut Medical Center, Beirut, Lebanon
| | - P A Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia
| | - C A Hudis
- Chief Executive Officer, American Society of Clinical Oncology, Alexandria, USA
| | - S Ohno
- Center of Breast Oncology, Cancer Institute Hospital, Koto-Ku, Tokyo, Japan
| | - A H Partridge
- Division of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - G W Sledge
- Department of Medicine, Stanford University, Stanford, USA
| | - I E Smith
- Breast Unit, Royal Marsden Hospital, London, UK
| | - K A Gelmon
- Department of Medical Oncology, BC Cancer Agency, Vancouver, Canada
| |
Collapse
|
11
|
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28:3111. [PMID: 28327998 PMCID: PMC5834023 DOI: 10.1093/annonc/mdx036] [Citation(s) in RCA: 136] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
12
|
Toi M, Huang C, Im YH, Iwata H, Sohn J, Wang HC, Masuda N, Lin Y, Sakaguchi S, Bourayou N, Llombart A, Sledge G. MONARCH 2: Abemaciclib in combination with fulvestrant in Asian women with HR+, HER2- advanced breast cancer who progressed on endocrine therapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx654.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios C, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso M, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart M, Pierga J, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. Corrigendum to “3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)” [Breast 31 (February 2017) 244–259]. Breast 2017; 32:269-270. [DOI: 10.1016/j.breast.2017.01.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
14
|
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28:16-33. [PMID: 28177437 PMCID: PMC5378224 DOI: 10.1093/annonc/mdw544] [Citation(s) in RCA: 258] [Impact Index Per Article: 36.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Affiliation(s)
- F. Cardoso
- European School of Oncology & Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
| | - A. Costa
- European School of Oncology, Milan, Italy and European School of Oncology, Bellinzona, Switzerland
| | - E. Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - M. Aapro
- Breast Center, Genolier Cancer Center, Genolier, Switzerland
| | - F. André
- Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France
| | - C. H. Barrios
- Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil
| | - J. Bergh
- Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden
| | | | - L. Biganzoli
- Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - M. J. Cardoso
- Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
| | - L. Carey
- Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center
| | | | - G. Curigliano
- Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy
| | - V. Dieras
- Department of Medical Oncology, Institut Curie, Paris, France
| | - N. El Saghir
- NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut, Beirut, Lebanon
| | - A. Eniu
- Department of Breast Tumors, Cancer Institute ‘I. Chiricuta’, Cluj-Napoca, Romania
| | - L. Fallowfield
- Brighton & Sussex Medical School, University of Sussex, Falmer, UK
| | - D. Fenech
- Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta
| | - P. Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K. Gelmon
- BC Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada
| | - A. Gennari
- Department of Medical Oncology, Galliera Hospital, Genoa, Italy
| | - N. Harbeck
- Brustzentrum der Universitat München, Munich, Germany
| | - C. Hudis
- Breast Medicine Service, Memorial Sloan-Kettering Cancer Centre, New York, USA
| | - B. Kaufman
- Sheba Medical Center, Tel Hashomer, Israel
| | - I. Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - M. Mayer
- Advanced Breast Cancer.org, New York, USA
| | - H. Meijer
- Department of Radiation Oncology, Radvoud University Medical Center, Nijmegen, The Netherlands
| | - S. Mertz
- Metastatic Breast Cancer Network US, Inversness, USA
| | - S. Ohno
- Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan
| | - O. Pagani
- Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland
| | | | - F. Peccatori
- European School of Oncology, Milan, Italy and Bellinzona, Switzerland
| | - F. Penault-Llorca
- Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France
| | - M. J. Piccart
- Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - J. Y. Pierga
- Department of Medical Oncology, Institut Curie-Université Paris Descartes, Paris, France
| | - H. Rugo
- Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
| | - L. Shockney
- Department of Surgery and Oncology, Johns Hopkins Breast Center, Baltimore
| | - G. Sledge
- Indiana University Medical CTR, Indianapolis
| | - S. Swain
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
| | - C. Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany
| | - A. Tutt
- Breakthrough Breast Cancer Research Unit, King’s College London and Guy’s and St Thomas’s NHS Foundation Trust, London, UK
| | - D. Vorobiof
- Sandton Oncology Centre, Johannesburg, South Africa
| | - B. Xu
- Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - L. Norton
- Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York
| | - E. Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
15
|
Vaz Luis I, O'Neill A, Sepucha K, Miller KD, Baker E, Dang CT, Northfelt DW, Winer EP, Sledge GW, Schneider BP, Partridge A. Abstract P5-11-02: Survival benefit needed to undergo chemotherapy: Patients and physicians preferences. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-11-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Data regarding patients (pts) and physicians' preferences for modern adjuvant chemotherapy (CT) are limited. Prior studies suggested that most pts with early stage breast cancer were willing to receive 6 months of adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for modest survival benefits (e.g. most women would have accepted 3-6 months extension of life).
Methods: E5103 was a phase III trial which randomized node positive or high risk node negative breast cancer pts to receive adjuvant CT (doxorubicin, cyclophosphamide and paclitaxel) with either placebo or bevacizumab. Telephone based surveys were administered to all pts enrolled on E5103 between 01/Jan/10 and 08/Jun/10, as part of a Decision-Making/Quality of Life component. Results presented here are part of the 18 months post-enrollment follow-up. Pts were asked to rate the survival benefit needed to justify 6 months of CT. A complementary survey was sent to all physicians who registered at least one pt on E5103.
Results: 465 out of 519 eligible pts (90%) responded to this survey at 18 months. Main reasons for non response were: inability to reach the patient (6%) or patient refusal (2%). Median pts age was 51 (25-76); 42% of pts had at least a college degree. The majority had at least Stage II cancer.
179 (16%) physicians participated, among whom median age was 50 (35-70). The median years in practice was 17 (3-38); 78% of physicians worked on large size practices, 72% saw at least 5 new breast cancer pts/month, and 77% enroll between 1-4 pts on trials/month.
We found considerable variation in pts preferences particularly for modest survival benefits: a substantial minority of pts (24%) would consider 6 months of CT definitely worthwhile for 1 month survival benefit, 18% would possibly consider it and 56% would not. The percentage considering CT definitely worthwhile increased with greater benefit, but did not reach 100%, even with 24 months survival benefit. About half of pts considered 6 months of CT definitely worthwhile for 9 months benefit, 70% for 12 months and 84% for 24 months.
Physicians were less likely to accept CT for a small chance of benefit (34% of pts vs. 5% of physicians would definitely consider CT worthwhile for 2 months of benefit). For longer benefit, pts and physicians choices were similar (84% of pts vs. 92% of physicians would definitely consider CT worthwhile for 24 months benefit).
Table Yes, definitely worthwhileYes, maybeNo, not worthwhileNo answerConsider 6 months of CT to live:PtsPhysiciansPtsPhysiciansPtsPhysiciansPts/Physicians*1 month longer24%3%18%15%56%80%2%2 months longer34%5%23%32%41%60%2%6 months longer44%32%35%54%19%12%2%9 months longer53%51%34%42%11%5%2%12 months longer70%75%23%22%5%1%2%24 months longer84%92%12%5%2%1%2%n Pts= 465; n Physicians= 179; * equal results in both groups
Conclusions: This subgroup of pts who had undergone modern adjuvant CT in a large multicenter randomized controlled trial and these physicians who registered pts on the same trial had different cutoffs for acceptable levels of benefits and risks when considering adjuvant chemotherapy. It is important to engage pts in determining whether CT is or is not a "reasonable" option for treatment.
Citation Format: Vaz Luis I, O'Neill A, Sepucha K, Miller KD, Baker E, Dang CT, Northfelt DW, Winer EP, Sledge GW, Schneider BP, Partridge A. Survival benefit needed to undergo chemotherapy: Patients and physicians preferences. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-11-02.
Collapse
Affiliation(s)
- I Vaz Luis
- Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, NY, NY; Mayo Clinic, Scottsdale, AR; Stanford University, Stanford, CA
| | - A O'Neill
- Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, NY, NY; Mayo Clinic, Scottsdale, AR; Stanford University, Stanford, CA
| | - K Sepucha
- Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, NY, NY; Mayo Clinic, Scottsdale, AR; Stanford University, Stanford, CA
| | - KD Miller
- Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, NY, NY; Mayo Clinic, Scottsdale, AR; Stanford University, Stanford, CA
| | - E Baker
- Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, NY, NY; Mayo Clinic, Scottsdale, AR; Stanford University, Stanford, CA
| | - CT Dang
- Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, NY, NY; Mayo Clinic, Scottsdale, AR; Stanford University, Stanford, CA
| | - DW Northfelt
- Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, NY, NY; Mayo Clinic, Scottsdale, AR; Stanford University, Stanford, CA
| | - EP Winer
- Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, NY, NY; Mayo Clinic, Scottsdale, AR; Stanford University, Stanford, CA
| | - GW Sledge
- Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, NY, NY; Mayo Clinic, Scottsdale, AR; Stanford University, Stanford, CA
| | - BP Schneider
- Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, NY, NY; Mayo Clinic, Scottsdale, AR; Stanford University, Stanford, CA
| | - A Partridge
- Dana Farber Cancer Institute, Boston, MA; Massachusetts General Hospital, Boston, MA; Indiana University Cancer Center, Indianapolis, IN; Memorial Sloan Kettering Cancer Center, NY, NY; Mayo Clinic, Scottsdale, AR; Stanford University, Stanford, CA
| |
Collapse
|
16
|
Sparano J, Gray R, Zujewski J, Makower D, Pritchard K, Albain K, Hayes D, Geyer C, Dees C, Perez E, Keane M, Vallejos C, Goggins T, Mayer I, Brufsky A, Toppmeyer D, Kaklamani V, Atkins J, Olson J, Sledge G. 5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31935-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol 2014; 25:1871-1888. [PMID: 25234545 PMCID: PMC4176456 DOI: 10.1093/annonc/mdu385] [Citation(s) in RCA: 284] [Impact Index Per Article: 28.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 08/11/2014] [Indexed: 12/23/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
| | - A Costa
- European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
| | - L Norton
- Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - M Aapro
- Division of Oncology, Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Gustave-Roussy Institute, Villejuif, France
| | - C H Barrios
- Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden
| | - L Biganzoli
- Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy
| | - K L Blackwell
- Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA
| | - M J Cardoso
- Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - T Cufer
- University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia
| | - N El Saghir
- NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - L Fallowfield
- Brighton & Sussex Medical School, University of Sussex, Falmer, UK
| | - D Fenech
- Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta
| | - P Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- BC Cancer Agency, Vancouver, Canada
| | - S H Giordano
- Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA
| | - J Gligorov
- APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, AROME, Paris, France
| | - A Goldhirsch
- Program of Breast Health, European Institute of Oncology, Milan, Italy
| | - N Harbeck
- Brustzentrum der Universität München, Munich, Denmark
| | - N Houssami
- Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia
| | - C Hudis
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B Kaufman
- Sheba Medical Center, Tel Hashomer, Israel
| | - I Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - U N Lin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - S D Merjaver
- University of Michigan Medical School and School of Public Health, Ann Arbor, USA
| | - E B Nordström
- Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden
| | - O Pagani
- Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland
| | - A Partridge
- Department Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA
| | - F Penault-Llorca
- Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France
| | - M J Piccart
- Department of Medicine, Institut Jules Bordet, Brussels, Belgium
| | - H Rugo
- Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
| | - G Sledge
- Indiana University Medical CTR, Indianapolis, USA
| | - C Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany
| | - L Van't Veer
- Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - D Vorobiof
- Sandton Oncology Centre, Johannesburg, South Africa
| | - C Vrieling
- Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland
| | - N West
- Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK
| | - B Xu
- Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - E Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
18
|
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014; 23:489-502. [PMID: 25244983 DOI: 10.1016/j.breast.2014.08.009] [Citation(s) in RCA: 194] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 08/12/2014] [Indexed: 12/25/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
| | - A Costa
- European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
| | - L Norton
- Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - M Aapro
- Division of Oncology, Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Gustave-Roussy Institute, Villejuif, France
| | - C H Barrios
- Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden
| | - L Biganzoli
- Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy
| | - K L Blackwell
- Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA
| | - M J Cardoso
- Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - T Cufer
- University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia
| | - N El Saghir
- NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - L Fallowfield
- Brighton & Sussex Medical School, University of Sussex, Falmer, UK
| | - D Fenech
- Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta
| | - P Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- BC Cancer Agency, Vancouver, Canada
| | - S H Giordano
- Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA
| | - J Gligorov
- APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, Arome, Paris, France
| | - A Goldhirsch
- Program of Breast Health, European Institute of Oncology, Milan, Italy
| | - N Harbeck
- Brustzentrum der Universität München, Munich, DE, USA
| | - N Houssami
- Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia
| | - C Hudis
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B Kaufman
- Sheba Medical Center, Tel Hashomer, Israel
| | - I Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - U N Lin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | - M Mayer
- Advanced BC.org, New York, USA
| | - S D Merjaver
- University of Michigan Medical School and School of Public Health, Ann Arbor, USA
| | - E B Nordström
- Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden
| | - O Pagani
- Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland
| | - A Partridge
- Department Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA
| | - F Penault-Llorca
- Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France
| | - M J Piccart
- Department of Medicine, Institut Jules Bordet, Brussels, Belgium
| | - H Rugo
- Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - G Sledge
- Indiana University Medical CTR, Indianapolis, USA
| | - C Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, DE, Germany
| | - L Van't Veer
- Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - D Vorobiof
- Sandton Oncology Centre, Johannesburg, South Africa
| | - C Vrieling
- Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland
| | - N West
- Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK
| | - B Xu
- Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - E Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | | |
Collapse
|
19
|
Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer 2014; 111:1241-8. [PMID: 25117820 PMCID: PMC4453857 DOI: 10.1038/bjc.2014.430] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2014] [Revised: 06/26/2014] [Accepted: 07/08/2014] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No reliable markers are available for predicting bevacizumab-induced hypertension. METHODS A genome-wide association study (GWAS) was performed in the phase III bevacizumab-based adjuvant breast cancer trial, ECOG-5103, to evaluate for an association between genotypes and hypertension. GWAS was conducted in those who had experienced systolic blood pressure (SBP) >160 mm Hg during therapy using binary analysis and a cumulative dose model for the total exposure of bevacizumab. Common toxicity criteria (CTC) grade 3-5 hypertension was also assessed. Candidate SNP validation was performed in the randomised phase III trial, ECOG-2100. RESULTS When using the phenotype of SBP>160 mm Hg, the most significant association in SV2C (rs6453204) approached and met genome-wide significance in the binary model (P=6.0 × 10(-8); OR=3.3) and in the cumulative dose model (P=4.7 × 10(-8); HR=2.2), respectively. Similar associations with rs6453204 were seen for CTC grade 3-5 hypertension but did not meet genome-wide significance. Validation study from ECOG-2100 demonstrated a statistically significant association between this SNP and grade 3/4 hypertension using the binary model (P-value=0.037; OR=2.4). CONCLUSIONS A genetic variant in SV2C predicted clinically relevant bevacizumab-induced hypertension in two independent, randomised phase III trials.
Collapse
Affiliation(s)
- B P Schneider
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - L Li
- Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
| | - F Shen
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - K D Miller
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - M Radovich
- Department of General Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - A O'Neill
- Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
| | - R J Gray
- Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
| | - D Lane
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - D A Flockhart
- Indiana Institute for Personalized Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - G Jiang
- Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
| | - Z Wang
- Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
| | - D Lai
- Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
| | - D Koller
- Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
| | - J H Pratt
- Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - C T Dang
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - D Northfelt
- Department of Medicine, Mayo Clinic, Scottsdale, AZ 85054, USA
| | - E A Perez
- Mayo Clinic, Jacksonville, FL 32224, USA
| | - T Shenkier
- BCCA – Vancouver Cancer Center, Vancouver, BC, V5Z 4E6, USA
| | - M Cobleigh
- Department of Internal Medicine , Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA
| | - M L Smith
- Research Advocacy Network, Plano, TX 75093, USA
| | - E Railey
- Research Advocacy Network, Plano, TX 75093, USA
| | - A Partridge
- Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
| | - J Gralow
- University of Washington, Seattle, WA 98195, USA
| | - J Sparano
- Department of Oncology, Montefiore Hospital and Medical Center, Bronx, NY 10467, USA
| | - N E Davidson
- Cancer Institute and University of Pittsburgh Cancer Center, Pittsburgh, PA 15232, USA
| | - T Foroud
- Department of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
| | - G W Sledge
- Department of Medicine, Stanford University, Stanford, CA 94305, USA
| |
Collapse
|
20
|
Sacco RL, Smith SC, Holmes D, Shurin S, Brawley O, Cazap E, Glass R, Komajda M, Koroshetz W, Mayer-Davis E, Mbanya JC, Sledge G, Varmus H. Accelerating progress on non-communicable diseases. Lancet 2013; 382:e4-5. [PMID: 21933747 DOI: 10.1016/s0140-6736(11)61477-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- R L Sacco
- American Heart Association, Dallas, TX 75231, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Radovich M, Atale R, Clare SE, Sledge GW, Schneider BP. Abstract PD05-06: Next-generation RNA-sequencing of triple negative breast cancer compared to donated microdissected normal epithelium and adjacent normal tissues. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-pd05-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: There currently exists an inadequate understanding of the transcriptional dysregulation that differentiates Triple-Negative Breast Cancer (TNBC) from normal breast epithelium. Currently, a popular comparator in gene expression studies is to use normal tissue adjacent to the primary tumor. Using RNA-seq data of TNBCs and donated microdissected normal breast epithelium from our institution combined with TNBCs and adjacent normal tissues from the The Cancer Genome Atlas (TCGA), we sought to determine the differential regulation of genes between TNBC compared to normal breast epithelium and adjacent normal tissues.
Methods: Normal breast tissues from healthy pre-menopausal volunteers with no history of disease were procured from the Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer Center. To eliminate bias from stromal tissue, normal tissues were laser capture microdissected for ductal epithelium. RNA from 20 microdissected normal breast tissues and 10 TNBCs from our institution were sequenced on a Life Technologies SOLiD sequencer. This data was combined with RNA-seq data from an additional 77 TNBCs and 10 adjacent normal tissues from the TCGA Data Portal. The merged gene expression values (RPKM) were quantile normalized, batch effect corrected, and submitted for differential gene expression analysis using Partek Genomics Suite. Differentially expressed genes were statistically determined with cutoffs of FDR<5% and Fold Change>±2. Pathway and network analyses utilized Ingenuity Pathway Analysis.
Results: Principal components analysis (PCA) of all expressed protein coding genes revealed a close association of adjacent normal tissues to TNBCs whereas microdissected normal breast tissues were starkly separated. In comparing these 3 tissue types, 3841 genes were differentially expressed between TNBC vs. donated microdissected normal of which 1627 genes were also differentially expressed between adjacent normal vs. donated microdissected normal. The PCA along with the differential expression support the notion that adjacent normal gene expression is strongly influenced by the primary tumor, and in a significant set of genes, adjacent normal gene expression mimics the expression of primary tumors. The differential gene expression analysis also revealed 1240 genes that were restricted solely to the TNBC vs. donated microdissected normal that were not detected when TNBCs were compared to adjacent normal tissues. Examination of these genes reveals several potential kinase drug targets, genes involved in notch signaling, metabolism, cell cycle among other key cancer pathways. Preliminary analysis of the non-coding RNA component also reveals the same pattern of dysregulation in cancer associated microRNAs and lincRNAs.
Conclusions: Gene expression within adjacent normal tissues is significantly impacted by the primary tumor and donated microdissected normal breast epithelium from healthy volunteers may be an optimal comparator for use in next-generation RNA sequencing breast cancer studies. Use of this comparator may identify therapeutic targets that would not otherwise be detected when using adjacent normal tissue as controls.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD05-06.
Collapse
Affiliation(s)
- M Radovich
- Indiana University School of Medicine, Indianapolis, IN
| | - R Atale
- Indiana University School of Medicine, Indianapolis, IN
| | - SE Clare
- Indiana University School of Medicine, Indianapolis, IN
| | - GW Sledge
- Indiana University School of Medicine, Indianapolis, IN
| | - BP Schneider
- Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
22
|
Miller KD, O'Neill A, Dang C, Northfelt D, Gradishar W, Sledge GW. Abstract P5-17-01: Bevacizumab (B) in the adjuvant treatment of breast cancer - first toxicity results from Eastern Cooperative Oncology Group trial E5103. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-17-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A previous feasibility trial (E2104 – Ann Oncol 23(2):331–7,2012) suggested incorporation of B into anthracycline-containing adjuvant therapy was feasible but ongoing cardiac monitoring was required to define the true impact of B on cardiac function.
Methods: Patients (pts) were assigned 1:2:2 to one of three treatment arms. In addition to doxorubicin and cyclophosphamide followed by weekly paclitaxel, patients received either placebo (Arm A – AC>T) or B during chemotherapy (Arm B - BAC>BT), or B during chemotherapy followed by B monotherapy (15 mg/kg q3wk) for an additional 10 cycles (Arm C – BAC>BT>B). Randomization was stratified and B dose adjusted for choice of AC schedule (classical q3wk − 15 mg/kg; dose dense(dd) q2 wk − 10 mg/kg). When indicated, radiation and hormonal therapy were administered concurrently with B (for Arm C pts). The primary cardiac endpoint was the incidence of clinically apparent cardiac dysfunction (CHF)defined as symptomatic decline in left ventricular ejection fraction (LVEF) to below the lower limit of normal (LLN) or symptomatic diastolic dysfunction as assessed by independent review. Cumulative toxicity data as of Jan 23, 2012 are presented.
Results: From 11.07 to 2.11, 4994 pts were enrolled. Median age was 52; 80% received ddAC. Chemotherapy associated toxicities including myelosuppression (Grade 4 neutropenia 16/20/19%) and neuropathy (Grade ≥ 3 8/8/8%) were similar across all arms. Grade ≥ 3 hypertension/thrombosis/proteinuria/hemorrhage was reported by 7/3/<1/<1% of B-treated pts. 99 pts developed CHF, most commonly reported at the post-AC or post-T evaluation. After a median follow-up of 26 months, the cumulative incidence of clinical CHF at 15 months from randomization in Arm A/B/C was 1.0/1.7/2.9% respectively. Median age of CHF pts was 57; median baseline LVEF of CHF pts was 60.
Conclusion: Incorporation of B into anthracycline and taxane containing adjuvant therapy results in a significant but small increase in clinical CHF. The rate of clinical CHF is similar to that predicted by E2104 (2.5–2.9%) and reported In the FDA label for anthracycline pre-treated pts(3.8%). No unexpected toxicities were encountered.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-17-01.
Collapse
Affiliation(s)
- KD Miller
- Indiana University Melvin and Bren Simon Cancer Center; Dana Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Mayo Clinic; Northwestern University
| | - A O'Neill
- Indiana University Melvin and Bren Simon Cancer Center; Dana Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Mayo Clinic; Northwestern University
| | - C Dang
- Indiana University Melvin and Bren Simon Cancer Center; Dana Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Mayo Clinic; Northwestern University
| | - D Northfelt
- Indiana University Melvin and Bren Simon Cancer Center; Dana Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Mayo Clinic; Northwestern University
| | - W Gradishar
- Indiana University Melvin and Bren Simon Cancer Center; Dana Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Mayo Clinic; Northwestern University
| | - GW Sledge
- Indiana University Melvin and Bren Simon Cancer Center; Dana Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Mayo Clinic; Northwestern University
| |
Collapse
|
23
|
Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I, Winer E. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012; 21:242-52. [PMID: 22425534 DOI: 10.1016/j.breast.2012.03.003] [Citation(s) in RCA: 242] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
The 1st international Consensus Conference for Advanced Breast Cancer (ABC 1) took place on November 2011, in Lisbon. Consensus guidelines for the management of this disease were developed. This manuscript summarizes these international consensus guidelines.
Collapse
Affiliation(s)
- F Cardoso
- European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Perez EA, Ballman KV, Reinholz MM, Dueck AC, Cheng H, Jenkins RB, McCullough AE, Chen B, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Geiger XJ, Ingle JN, Tenner KS, Harris LN, Gralow JR, Rimm DL. PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-pd05-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Prediction of benefit from trastuzumab in patients (pts) with HER2+ breast cancer remains an important goal. We sought to investigate the predictive value of quantitative measurement of HER2, HER3, HER4, EGFR, ER and PTEN protein expression on the benefit of trastuzumab in the phase III HER2+ adjuvant N9831 study for pts randomized to chemotherapy alone (Arm A) or chemotherapy with sequential (Arm B) or concurrent trastuzumab (Arm C).
Methods: For each marker, we evaluated quantitative expression, relationship with demographic data, and association with disease-free survival (DFS) of pts. Freshly cut tissue microarray slides with up to three-fold redundancy per specimen from the N9831 cohort were treated identically using the AQUA (Camp, et al; Nat Med 2002, JCO 2008) method of quantitative immunofluorescence for each marker. HER2 was tested with CB11 (mouse monoclonal, Biocare, Inc.) and preliminary results were available for 698 of nearly 1400 pt specimens to be tested. The minimum value per pt was used in statistical analysis. Specimens were classified with high versus low expression based on a median value cutpoint for each marker. Median follow-up was 7.0 yrs.
Results: Quantitative HER2 was compared with centrally performed HER2 testing by IHC and FISH. Median quantitative HER2 via AQUA was 10,017 units for the HER2 IHC 3+ group (n=607) versus 1058, 831, and 970 for the HER2 IHC 2+ (n=68), 1+ (n=11), and 0 (n=11) groups, respectively. The Spearman correlation between quantitative HER2 and FISH HER2/CEP17 ratio was 0.32 (p<0.001). High quantitative HER2 was associated with lower percentage of hormone receptor positivity (48% vs 59%, chi-sq p=0.003) but not associated with age, race, nodal positivity, tumor histology, grade, or size. High HER2 did not impact DFS in any arm of the study (See Table). Data for additional HER2 testing, HER3, HER4, EGFR, ER and PTEN are in process and will be ready by September, 2011.
Conclusions: Similar to results based on standard HER2 testing by IHC and FISH in N9831, quantitative HER2 did not impact benefit from adjuvant trastuzumab. Results for additional markers will be presented. Our complete quantitative results for a second epitope on HER2, HER3, HER4, ER and EGFR will be the first report of these markers in a large patient cohort in the adjuvant setting.
Disease Free Survival
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD05-03.
Collapse
Affiliation(s)
- EA Perez
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - KV Ballman
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - MM Reinholz
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - AC Dueck
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - H Cheng
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - RB Jenkins
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - AE McCullough
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - B Chen
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - NE Davidson
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - S Martino
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - PA Kaufman
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - LA Kutteh
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - GW Sledge
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - XJ Geiger
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - JN Ingle
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - KS Tenner
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - LN Harris
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - JR Gralow
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| | - DL Rimm
- 1Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Angeles Clinic and Research Institute, Santa Monica, CA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Oncology Associates of Cedar Rapids, Cedar Rapids, IA; Indiana University Medical Center Cancer Pavillion, Indianapolis, IN; Yale University, New Haven, CT; Seattle Cancer Care Alliance, Seattle, WA
| |
Collapse
|
25
|
Gökmen-Polar Y, Toroni RA, Goswami C, Sanders KL, Mehta R, Sirimalle U, Tanasa B, Shen C, Li L, Ivan M, Badve S, Sledge GW. P5-06-01: Gene Expression Analysis of Resistance to Bevacizumab in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-06-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), had promising therapeutic efficacy in breast cancer. However, intrinsic or acquired resistance is common in the clinic. To improve our understanding of the underlying mechanisms of resistance to bevacizumab (BEV), we report the gene expression analysis of resistance to bevacizumab in a VEGF-overexpressing xenograft model of ER-positive breast cancer.
Methods: We developed a nude mouse xenograft model of resistance to anti-VEGF therapy with BEV in which MCF-7 control (ML20) or MCF-7 VEGF (MV165) transfectants were implanted in mammary fat pads, allowed to grow, then treated with BEV, with collection of tumor at early or late time points (while responding (R) to or progressing (NR) on anti-VEGF therapy). To elucidate differentially expressed gene profiling associated with tumor resistance to BEV, we performed whole-genome gene expression analysis (Human WG-6v2 Expression Beadchips, Illumina) and miRNA profiling (TaqMan ***ArrayHuman MicroRNAA+B Cards Set v3.0, Applied Biosystems). Validation of the chosen genes was performed using quantitative real-time RT-PCR (qRT-PCR).
Results: Gene expression analysis revealed differentially regulated genes in the MV165-NR group compared with the MV165-R group. Among the significant genes, Follistatin (FST) and HEY2 were the top genes upregulated in NR compared to R by ANOVA. Expression of HEY2 is induced by the Notch signaling pathway. Using qRT-PCR, we validated the expression of FST and Notch in our system. FST was significantly decreased (Fold change= −3.2; P=0.03) in the R group compared with vehicle in MV165 xenografts. In contrast to R group, FST was upregulated significantly (Fold change= 9.3; P=0.05) in the NR group. Notch4 displayed increased levels of expression in NR group, but it did not reach significance (P=0.23). In addition, correlation of mRNA and miRNA profiles showed that miRNAs targeting FST and Notch4 were differentially regulated in NR group compared to R group in MV165 xenograft tumors. Among the miRNAs, TGF-β-induced oncomiR miR-181a is up-regulated in NR and targets both FST and Notch4. Other miRNAs that target both Notch4 and FST include miR-1, miR-133a, miR-133b, and mir-449b. Conclusion: Our data serve as a potential mechanistic explanation for acquired resistance to bevacizumab. These data may shed light on the transitory effect of BEV observed in the E2100 firstline metastatic breast cancer trial, where VEGF-targeted therapy prolongs progression-free survival in metastatic breast cancer without improving overall survival.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-06-01.
Collapse
Affiliation(s)
- Y Gökmen-Polar
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - RA Toroni
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - C Goswami
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - KL Sanders
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - R Mehta
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - U Sirimalle
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - B Tanasa
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - C Shen
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - L Li
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - M Ivan
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - S Badve
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| | - GW Sledge
- 1Indiana University School of Medicine, Indianapolis, IN; University of Medicine and Pharmac, La Jolla, CA
| |
Collapse
|
26
|
Miller KD, Perkins SM, Badve SS, Sledge GW, Schneider BP. OT3-01-05: PARP Inhibition after Preoperative Chemotherapy in Patients with Triple-Negative Breast Cancer (TNBC) or Known BRCA 1/2 Mutations: Hoosier Oncology Group BRE09-146. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot3-01-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Based on recently reported I-SPY trial, TNBC patients who had residual disease category II or III had 2-year disease free survival (DFS) of only ∼40% (J Clin Oncol 2009;27:18s). Currently, no standard systemic therapy exists for this high-risk group. It represents a real opportunity to explore the potential impact of novel therapies. Recent laboratory and early clinical studies (Nature 2005;434:913) identified a unique sensitivity to DNA-damaging chemotherapy and PARP inhibition. We initiated a randomized phase II trial of DNA-damaging chemotherapy (cisplatin) or PARP-inhibition + cisplatin in TNBC patients with substantial residual invasive disease after standard anthracycline and/or taxane containing neoadjuvant chemotherapy.
Methods: To ensure a high-risk population, patients must have residual disease category 0–2 based on the Miller-Payne classification system, residual cancer burden classification II or III, residual lymph node involvement, or at least 2 cm of residual invasive disease in the breast. After completion of standard radiation therapy (when indicated), patients are randomized 1:1 to cisplatin (75 mg/M2 IV Day 1 every 3 weeks x 4 cycles) alone or in combination with PARP inhibition (PF-01367338 — 24 mg IV D1, 2, 3 of each 3 week cycle with a single dose escalation to 30 mg in the absence of significant toxicity in cycle 1 followed by maintenance PARP inhibition weekly x 24 weeks). The primary objective is 2-year DFS. To detect an improvement in 2-year DFS from 40% with cisplatin alone to 63.2% in the cisplatin + PF-01367338 arm (corresponding to HR=0.5), with 80% power using a one-side log-rank test with 0.10 level of significance, 102 patients are required in the primary analysis. Secondary objectives include safety, 1-year DFS, overall survival, and biomarkers of tumor recurrence, resistance to chemotherapy and/or PARP inhibition. Two dose escalation safety cohorts (N=13) were completed without dose limiting toxicity; the randomized portion began enrolment in 11/2010 has enrolled 20 patients as of 05/2011.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT3-01-05.
Collapse
Affiliation(s)
- KD Miller
- 1Indiana University Melvin and Bren Simon Cancer Center
| | - SM Perkins
- 1Indiana University Melvin and Bren Simon Cancer Center
| | - SS Badve
- 1Indiana University Melvin and Bren Simon Cancer Center
| | - GW Sledge
- 1Indiana University Melvin and Bren Simon Cancer Center
| | - BP Schneider
- 1Indiana University Melvin and Bren Simon Cancer Center
| |
Collapse
|
27
|
Mina LA, Gokmen-Polar Y, Goswami C, Storniolo AM, Li L, Badve S, Sledge GW. P2-13-01: Gene Profiling of Whole Blood May Identify Patients with BRCA Mutations. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:The BRCA1 and the BRCA2 proteins play a role in DNA repair and confer genomic stability to the cell. Identifying BRCA mutation carriers has become an important tool for prevention as well as guiding therapy in cancer patients. We proposed to test the hypothesis that gene expression analysis of peripheral whole blood can reliably detect these mutations.
Materials and methods: Following IRB approval, 10cc of blood was collected from 36 women (BRCA1 (n=8), BRCA2 (n=9), Hereditary breast cancer without BRCA (FAM) (n=7), sporadic breast cancer (SPO) (n=11)). 3 of BRCA1 and 5 of BRCA2 samples were from women without cancer. Following RNA extraction (using the method described by Beekman et al) and quality assessment, Illumina® Whole-Genome DASL™ microarray (Human Ref-8 BeadChips) analysis was performed. The raw data was normalized and analyzed using Partek® Genomic Suite. Differentially expressed genes were identified using ANOVA analysis. Geneset specific supervised analysis was performed to visualize the inherent similarities and differences in the gene expression amongst different groups for 1) DNA repair and 2) Immune-system-related genes. Ingenuity Pathway Analysis (IPA) was performed to interpret the data in the context of biological processes, pathways and networks.
Results: Twenty-nine of the 87 immune-related genes were up-regulated in BRCA1 and BRCA2 groups compared to SPO or FAM groups; these included IL7R, CD53, CD2, CD48 and HLA-DRA. Twenty-five of the 79 DNA repair genes were up-regulated in BRCA1 and BRCA2; these included FANCC, RAD51L3, MSH2, MSH6 and PCNA. In IPA analysis, the comparison of BRCA1 vs. REST (BRCA2 + FAM + SPO) showed a strong immunologic signal, with the top altered biological processes including “Immunologic disease”, “Infection mechanism”, “Immune cell trafficking” and “cell-mediated immune response “. The top 5 canonical pathways also reflected a similar pattern and included “iCOS-iCOSL Signaling in T Helper Cells”, “OX40 Signaling Pathway”, “Calcium-induced T Lymphocyte”, “Apoptosis Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes” and “Protein Ubiquitination Pathway”. When BRCA2 was compared with the REST (BRCA1 + FAM + SPO), a much weaker signal was noted with none of the canonical pathways being significantly altered. PAM analysis showed that a set of 16 genes could differentiate the BRCA patients from the rest with an error rate of 5%. Further validation of this geneset is being performed.
Conclusion: Gene profiling in whole blood may offer an easy, reliable and inexpensive way to identify patients with BRCA mutation. Further studies are currently underway to validate our results in a larger patient population.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-13-01.
Collapse
Affiliation(s)
- LA Mina
- 1Indiana University School of Medicine, Indianapolis, IN
| | - Y Gokmen-Polar
- 1Indiana University School of Medicine, Indianapolis, IN
| | - C Goswami
- 1Indiana University School of Medicine, Indianapolis, IN
| | - AM Storniolo
- 1Indiana University School of Medicine, Indianapolis, IN
| | - L Li
- 1Indiana University School of Medicine, Indianapolis, IN
| | - S Badve
- 1Indiana University School of Medicine, Indianapolis, IN
| | - GW Sledge
- 1Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
28
|
Audet RM, Changyu S, Duchnowska R, Adamowicz K, Zok J, Rogowski W, Litwiniuk M, Debska S, Jaworska M, Foszczynska-Kloda M, Kulma-Kreft M, Zabkowska K, Jassem J, Edgerton S, Vang NK, Thor A, Chang J, Miller K, Sledge GW, Leyland-Jones B. P5-01-06: Gene Copy Number and Expression of TYMP and TYMS Are Predictive of Outcome in Breast Cancer Patients Treated with Capecitabine. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-01-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The efficacy of the pro-drug capecitabine (C) may be affected by the expression of thymidylate synthase (TYMS) and thymidine phosphorylase (TYMP), respectively the target and the activating enzyme of C, as well as dihydrofolate reductase (DHFR) that provides a key intermediate.
Method: In this retrospective study, expression and gene copy number (GCN) of the above enzymes were assessed and correlated with time-to progression (TTP) and progression-free survival (PFS) of adult female patients with pathologically confirmed breast cancer and locally advanced or metastatic disease treated with C 1000 mg/m2 BID days 1–14 of a 21-day cycle. TYMS, TYMP and DHFR GCN were scored using custom made FISH probes (Dako, Denmark) in at least 60 morphologically intact non-overlapping nuclei. FISH markers dichotomized as high/low by the median were correlated with TTP and PFS using Cox proportional hazard models in 65, 57 and 24 patients for TYMS, TYMP and DHFR probes respectively. Gene expression was analyzed using the whole genome cDNA-mediated annealing, selection extension and ligation (DASL) platform on total RNA extracted from FFPE tissue samples and correlated with TTP and PFS using Cox models in 75 patients. Correlations between GCN and expression were measured using both Pearson's and Spearman's correlation coefficients.
Results: Our interim results (ASCO 2011) showed that higher TYMS GCN was significantly associated with both decreased TTP (HR 1.76, 95% CI 1.07 to 2.90, p=0.026) and PFS (HR 1.86, 95% CI 1.14 to 3.04, p=0.036) in the overall patient population. We now observe 1) a statistically significant positive correlation between TYMS GCN and expression (Pearson 0.26, p=0.049; Spearman 0.25, p=0.056); 2) a trend towards worse outcome with higher TYMS expression in a) the overall population (TTP-HR 1.23, 95% CI 0.93 to 1.64, p=0.148), b) in ER+ patients (TTP-HR 1.46, 95% CI 0.97 to 2.19, p=0.07) as well as in c) HER2− patients (TTP-HR 1.17, 95% CI 0.85 to 1.61, p=0.343), 3) a statistically significant association between higher TYMP expression and longer PFS, but not TTP in ER+ and HER2− patients (table).
Discussion: Our ASCO 2011 analysis showed that high TYMS GCN is predictive of poor outcome in ER+ and HER2− patients, consistent with the fact it is the target of C. Here, we show that 1) expression of TYMS is significantly correlated with GCN 2) higher TYMS expression demonstrates the same trend towards poor outcome in ER+ and HER2− patients as in FISH, 3) higher TYMP expression is significantly associated with longer PFS in ER+ and HER2−patients, consistent with its C activating role. Differential sensitivity between FISH and DASL might be explained by the fact that DASL is performed in a pool of RNA coming from many cellular types, whereas FISH is scored selectively in tumor cells. These findings suggest that TYMS and TYMP GCN and expression can be useful predictive markers of C sensitivity in human breast cancer.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-01-06.
Collapse
Affiliation(s)
- RM Audet
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - S Changyu
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - R Duchnowska
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - K Adamowicz
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - J Zok
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - W Rogowski
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - M Litwiniuk
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - S Debska
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - M Jaworska
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - M Foszczynska-Kloda
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - M Kulma-Kreft
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - K Zabkowska
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - J Jassem
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - S Edgerton
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - Nielsen K Vang
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - A Thor
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - J Chang
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - K Miller
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - GW Sledge
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| | - B Leyland-Jones
- 1VM Institut of Research, Montreal, QC, Canada; Medical University of Gdansk, Gdansk, Poland; Indiana University School of Medicine, Indianapolis, IN; Melvin and Bren Simon Cancer Center, Indianapolis; Emory University, Atlanta, GA; UC Denver School of Medicine, Aurora, CO; DAKO, Glostrup, Denmark; The Methodist Hospital Research Institute, Houston, TX; Military Institute of Medicine, Warsaw; Regional Oncology Center, Olsztyn; Poznan University of Medical Sciences; Regional Cancer Center, Lodz, MD; District Hospital, Wrocław, MD; West Pomeranian Oncology Center, Szczecin; Gdynia Oncology Center
| |
Collapse
|
29
|
Gökmen-Polar Y, Toroni RA, Goswami C, Sanders KL, Sirimalle U, Mehta R, Li L, Ivan M, Badve S, Sledge GW. P3-04-02: Bevacizumab Treatment Alters Intrinsic Subtypes in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-04-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Anti-vascular endothelial growth factor (anti-VEGF) therapy improves disease-free but not overall survival in metastatic breast cancer. To seek further insight on resistance to anti-VEGF antibody bevacizumab (BEV) at the molecular level, we developed breast cancer xenograft models allowing comparison of tumor response at different time-points. Here we report the gene expression and miRNA analyses of response and non-response to BEV in these models.
Methods: MCF-7 cells transfected with control vector (ML20) or VEGF (MV165) were implanted into the mammary fat pads of athymic mice. Tumors from short-term treatment with BEV (3 weeks; Responders to BEV, R) or long-term treatment (8 weeks; Non-Responders, NR) or with vehicle control group (V) were subjected to whole-genome gene expression analysis (Human WG-6v2 Expression Beadchips, Illumina) and miRNA profiling (TaqMan ArrayHuman MicroRNA A+B Cards Set v3.0, Applied Biosystems).Validation of the chosen genes was performed using quantitative real-time RT-PCR (qRT-PCR) and Immunohistochemistry (IHC). Results: Short-term treatment to BEV (3 weeks; 5 mg/kg, i.p./twice weekly) inhibited primary tumor growth significantly in MV165 xenografts compared with vehicle control, whereas BEV treatment did not affect the tumor growth in the ML20 model. MV165 xenografts progressed after 8 weeks of BEV treatment. Gene set enrichment analysis (GSEA) revealed that luminal A-related gene sets were enriched in MV165-R compared to MV165-NR group including DESMEDT (ESR1), SMID_Breast_Cancer_Luminal_A_up, and MASSARWEH_ Tamoxifen_Resistance_ Down. Myoepithelial-specific gene sets were upregulated in both the R and NR groups compared with the vehicle group. qRT-PCR analysis showed that estrogen receptor alpha (ESR1) representative for luminal A decreased significantly in the MV-165-NR group (P=0.001) compared to vehicle. In contrast, Cytokeratin 5 (KRT5) levels increased significantly in both R (P=0.02) and NR (P=0.03) groups. In addition, KRT14 was upregulated in R (P= 0.04) and in NR (P=0.14) group in comparison with the vehicle group, suggesting the upregulation of myoepithelial phenotype specific to BEV treated MV165 model, but not ML20 model. Similar results were obtained by IHC. Consistent with mRNA changes, ESR1 regulated miRNA such as miR-107 (P=0.007) and miRNA important in tamoxifen resistance such as mir-451 (P= 0.0003) were also altered in MV165-NR group compared to vehicle. Conclusion: These results suggest that treatment with BEV may alter the intrinsic subtypes in the presence of VEGF expression. These data may help to explain the variable results to anti-VEGF therapy based on the duration of BEV treatment.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-04-02.
Collapse
Affiliation(s)
| | - RA Toroni
- 1Indiana University School of Medicine, Indianapolis, IN
| | - C Goswami
- 1Indiana University School of Medicine, Indianapolis, IN
| | - KL Sanders
- 1Indiana University School of Medicine, Indianapolis, IN
| | - U Sirimalle
- 1Indiana University School of Medicine, Indianapolis, IN
| | - R Mehta
- 1Indiana University School of Medicine, Indianapolis, IN
| | - L Li
- 1Indiana University School of Medicine, Indianapolis, IN
| | - M Ivan
- 1Indiana University School of Medicine, Indianapolis, IN
| | - S Badve
- 1Indiana University School of Medicine, Indianapolis, IN
| | - GW Sledge
- 1Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
30
|
Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW. A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Ann Oncol 2011; 23:331-7. [PMID: 21821545 DOI: 10.1093/annonc/mdr344] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND E2104 was designed to evaluate the safety of two different strategies incorporating bevacizumab into anthracycline-containing adjuvant therapy as a precursor to a definitive randomized phase III trial. PATIENTS AND METHODS Patients were sequentially assigned to one of two treatment arms. In addition to dose-dense doxorubicin and cyclophosphamide followed by paclitaxel (Taxol) (ddAC→T), all patients received bevacizumab (10 mg/kg every 2 weeks × 26) initiated either concurrently with AC (Arm A: ddBAC→BT→B) or with paclitaxel (Arm B: ddAC→BT→B). The primary end point was incidence of clinically apparent cardiac dysfunction (CHF). RESULTS Patients enrolled were 226 in number (Arm A 104, Arm B 122). Grade 3 hypertension, thrombosis, proteinuria and hemorrhage were reported for 12, 2, 2 and <1% of patients, respectively. Two patients developed grade 3 or more cerebrovascular ischemia. Three patients in each arm developed CHF. There was no significant difference between arms in the proportion of patients with an absolute decrease in left ventricular ejection fraction of >15% or >10% to below the lower limit of normal post AC or post bevacizumab. CONCLUSIONS Incorporation of bevacizumab into anthracycline-containing adjuvant therapy does not result in prohibitive cardiac toxicity. The definitive phase III trial (E5103) was activated with systematic and extensive cardiac monitoring to define the true impact of bevacizumab on cardiac function.
Collapse
Affiliation(s)
- K D Miller
- Department of Medicine, Division of Hematology and Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA.
| | | | | | | | | |
Collapse
|
31
|
Radovich M, Clare SE, Sledge GW, Pardo I, Mathieson T, Kassem N, Hancock BA, Storniolo AMV, Rufenbarger C, Lillemoe HA, Sun J, Henry JE, Goulet R, Hilligoss EE, Siddiqui AS, Breu H, Sakarya O, Hyland FC, Muller MW, Popescu L, Zhu J, Hickenbotham M, Glasscock J, Ivan M, Liu Y, Schneider BP. Abstract PD01-08: Decoding the Transcriptional Landscape of Triple-Negative Breast Cancer Using Next-Generation Whole Transcriptome Sequencing. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-pd01-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative breast cancer (TNBC) has been plagued by the absence of targeted therapies. Discovery of therapeutic targets in TNBC has in part, been hampered by an inadequate understanding of the transcriptional biology of the normal breast as an optimal comparator. Using next-generation sequencing, we embarked on a study to compare the transcriptomes of TNBC and normal breast to comprehensively identify novel targets by analyzing all full length transcripts expressed in these tissues.
Methods: Normal breast tissues from healthy pre-menopausal volunteers with no history of disease were procured from the Susan G. Komen for the Cure® Tissue Bank at the IU Simon Cancer Center. To eliminate bias from stromal tissue, normal tissues were laser capture microdissected for ductal epithelium. cDNA libraries from 10 TNBC tumors and 10 normal breast tissues were sequenced on an Applied Biosystems (AB) SOLiD3 sequencer using 50bp fragment runs. For gene expression, mapping of reads to the genome was performed using the AB BioScope 1.2 Pipeline and outputs imported into Partek Genomics Suite for analysis. In Partek, mapped reads were cross-referenced against known genes from the UCSC database followed by statistical comparison of RPKM values for each gene between TNBC and normal. Dimensionality reduction analyses (PCA & Hierarchical clustering) and identification of Novel Transcribed Regions were also performed in Partek, whereas construction of gene networks was performed using Ingenuity Pathway Analysis. To identify gene fusions, partially mapped reads were interrogated utilizing a novel algorithm that searched for reads spanning exons from two different genes. Fusions that were supported by at least 3 reads (of which 2 had to be unique) were considered candidates and were subsequently validated. Results/Discussion: Sequencing produced 1.1 billion reads equaling 57.3GB of data of which 36.0GB (63%) mapped to the human genome. In comparing RPKM values between TNBC and Normal, we report 7140 RefSeq Genes, 22 pre-miRNAs, 109 lincRNA exons, and 15 ultraconserved regions that were differentially expressed between these tissues (FDR<0.01). Biological interpretation of these results reveals upregulation of genes and miRNAs involved in DNA repair, angiogenesis, and inhibitors of Estrogen Receptor-alpha. Some previous drug targets (e.g. EGFR and c-kit) were not found to be upregulated here which may explain lack of clinical success to date. Conversely, PARP was significantly upregulated and early trial results suggest a strong signal for efficacy with inhibition of PARP. We also surveyed the genome for Novel Transcribed Regions (NTRs), defined as areas of significant transcription where no annotated gene is present. When comparing between TNBC and Normal, we report 6408 NTRs to be differentially expressed (FDR<0.01). Lastly, when analyzing the dataset for gene fusions, we identified several gene fusions in the TNBC samples, though no individual fusion was present in more than one sample.
Conclusion: We report an extensive comparison of the transcriptomes of TNBC and normal ductal epithelium. We identified numerous genes previously unknown to be dysregulated in TNBC that can be utilized for therapeutic discovery.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD01-08.
Collapse
Affiliation(s)
- M Radovich
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - SE Clare
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - GW Sledge
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - I Pardo
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - T Mathieson
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - N Kassem
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - BA Hancock
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - AMV Storniolo
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - C Rufenbarger
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - HA Lillemoe
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - J Sun
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - JE Henry
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - R Goulet
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - EE Hilligoss
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - AS Siddiqui
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - H Breu
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - O Sakarya
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - FC Hyland
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - MW Muller
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - L Popescu
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - J Zhu
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - M Hickenbotham
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - J Glasscock
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - M Ivan
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - Y Liu
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| | - BP. Schneider
- Indiana University School of Medicine, Indianapolis, IN; Life Technologies, Inc, Foster City, CA; Cofactor Genomics, LLC, St. Louis, MO
| |
Collapse
|
32
|
Miller K, Estes M, Perkins S, Schneider B, Matei D, Storniolo A, Ingram D, Yoder M, Kern K, Sledge G. An Exploratory Study of the Biological Activity of Sunitinib as a Component of Neoadjuvant Therapy for Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-202] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The neoadjuvant setting provides an ideal opportunity to explore the impact of sunitinib alone and in combination with paclitaxel on the functional status of tumor vasculature as indicated by changes in tumor interstitial pressure (IFP) and circulating progenitor cell (CPC) subsets.Methods: Patients(pts.) with newly diagnosed stage Ic-IIIc breast cancer were treated with sunitinib monotherapy (100 mg Day 1; 37.5 mg D2-14) prior to the initiation of paclitaxel (80 mg/M2 D1,8,15 every 28 days x 4 cycles) with sunitinib (25 mg/d). IFP and CPC subsets were assessed at baseline and after sunitinib monotherapy. IFP was measured in three separate areas of the tumor using a micropressure transducer catheter; mean and highest IFP recorded were analyzed. Improvements in poly-chromatic flow cytometry allowed distinction of pro-angiogenic (pCPC = Live/AC133+CD34bright/CD31+CD45dim\), from non-angiogenic (nCPC = Live/AC133-CD34bright/CD31+/CD45dim\), CPCs that cannot be quantified separately using previously reported protocols1. Baseline CPC subsets were also compared to age and gender matched healthy controls.Results: From July 2008 to May 2009, 14 pts were enrolled; baseline and post-sunitinib IFP and CPC data are available for 12 and 11 pts respectively. The median age was 48 (range 32-69). Mean pretreatment tumor diameter was 3.2 cm. Sunitinib monotherapy was generally well tolerated; two patients developed grade III toxicities including hypertension (n=1) and hand-foot syndrome (n=1). Sunitinib significantly decreased mean IFP (18.87 mmHg vs. 6.38 mmHg; p=0.002); similar results were obtained when only the maximum IFP was considered (22.32 mmHg vs. 8.36 mmHg; p=0.003). pCPC frequency was not different between pts and healthy controls (0.099% vs. 0.076%, p=0.24) but the p:nCPC ratio was significantly higher in pts compared to healthy controls (3.26 vs. 1.46; p=0.001) suggesting a shift toward vascular damage and/or active angiogenesis. Both pCPC frequency (0.099 vs. 0.022; p=0.001) and p:nCPC ratio (3.26 vs. 0.78; p=0.001) significantly decreased after sunitinib monotherapy. Analysis of paclitaxel + sunitinib is too early (n=4).Conclusion: Sunitinib, through its effects on VEGF-mediated vascular permeability, markedly reduces tumor IFP. In addition sunitinib profoundly reduces pCPCs that are thought to be important for angiogenesis in human cancers. Accrual is ongoing (planned N=40). Analysis of IFP and CPC subsets after paclitaxel + sunitinib as well as additional correlates will be presented.1 Duda et al. (2007). Nat. Protocol 2, 805-810.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 202.
Collapse
Affiliation(s)
- K. Miller
- 1Indiana University Melvin and Bren Simon Cancer Center, IN,
| | - M. Estes
- 1Indiana University Melvin and Bren Simon Cancer Center, IN,
| | - S. Perkins
- 1Indiana University Melvin and Bren Simon Cancer Center, IN,
| | - B. Schneider
- 1Indiana University Melvin and Bren Simon Cancer Center, IN,
| | - D. Matei
- 1Indiana University Melvin and Bren Simon Cancer Center, IN,
| | - A. Storniolo
- 1Indiana University Melvin and Bren Simon Cancer Center, IN,
| | - D. Ingram
- 1Indiana University Melvin and Bren Simon Cancer Center, IN,
| | - M. Yoder
- 1Indiana University Melvin and Bren Simon Cancer Center, IN,
| | | | - G. Sledge
- 1Indiana University Melvin and Bren Simon Cancer Center, IN,
| |
Collapse
|
33
|
Radovich M, Clare S, Clare S, Pardo I, Hancock B, Sledge G, Rufenbarger C, Rufenbarger C, Storniolo A, Storniolo A, Mathieson T, Mathieson T, Sun J, Sun J, Henry J, Henry J, Hilligoss E, Elliott J, Richt R, Hickenbotham M, Glasscock J, Liu Y, Schneider B. Next-Generation Whole Transcriptome Sequencing of Triple-Negative Breast Tumors and Normal Tissues. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative breast cancer predominately affects pre-menopausal women and women of African-American descent and has been plagued by the absence of targeted therapies leading to poor survival. Using a new cutting edge technology, next-generation sequencing, we embarked on a study to analyze the whole transcriptomes of triple-negative tumors and normal tissues from pre-menopausal women in order to comprehensively identify new targets by analyzing all full length transcripts expressed in these tissues. This approach is independent of pre-determined gene selection as is common with microarrays, and allows for the analysis of RNA species that have not been previously profiled in breast cancer.Methods: cDNA libraries were created from RNA isolated from 8 triple-negative tumors and 2 normal breast tissues. Triple negative tumors were procured from Origene Technologies and normal breast tissues were procured from the Susan G. Komen for the Cure tissue bank at Indiana University. Normal samples were from healthy pre-menopausal volunteers with no history of disease. In order to eliminate bias from stromal tissue, normal samples were laser capture microdissected for ductal cells and RNA extracted from the excised tissue. cDNA libraries were prepared and subsequently sequenced on an Applied Biosystems (ABI) SOLiD3 sequencer using a 50bp fragment run. Mapping of whole reads to the human genome was performed using the SOLiD Analysis Pipeline Tool software (ABI) followed by a split-read alignment in order to map reads crossing exon-exon junctions. Gene expression profiles for each sample were then created and statistically compared to identify the most differentially expressed genes. In order to analyze for fusion genes, a split-read alignment of non-mapping reads to a composite transcriptome formed from previously mapped reads (clusters) was performed.Results: Sequencing of the 10 samples produced 513 million filtered reads equaling 25.66GB of data. Mapping of the reads to the genome revealed 1.14 million transcribed regions (exons). A preliminary analysis of gene expression shows 55.2% of the transcribed loci to have significant differential expression between tumor and normal. In a further analysis for gene fusions, several candidate fusions were bioinformatically detected. These are currently being reviewed and validated.Discussion: Herein we present a preliminary analysis of the transcriptomes of triple-negative breast cancers in comparison to normal tissues. A multitude of analyses are ongoing, including but not limited to: gene fusions, differentially expressed novel genes, novel transcripts, alternative splicing, intrinsic subtyping, and presence of viral genes. In addition 2 more triple-negative tumors and 8 normal samples will also be sequenced. In the current analysis, differentially expressed non-coding RNAs was highly pervasive among the samples indicating a major role of this RNA species in tumorigenesis. In addition, triple-negative breast cancers may contain fusion genes that could be “drivers” of this malignancy. Further validation of these differentially expressed RNAs and fusion genes in a larger set of samples with subsequent functional studies is planned.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6134.
Collapse
Affiliation(s)
| | - S. Clare
- 1Indiana University School of Medicine, IN,
| | - S. Clare
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | - I. Pardo
- 1Indiana University School of Medicine, IN,
| | - B. Hancock
- 1Indiana University School of Medicine, IN,
| | - G. Sledge
- 1Indiana University School of Medicine, IN,
| | - C. Rufenbarger
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | | | | | - A. Storniolo
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | | | - T. Mathieson
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | - J. Sun
- 1Indiana University School of Medicine, IN,
| | - J. Sun
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | - J. Henry
- 1Indiana University School of Medicine, IN,
| | - J. Henry
- 2Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, IN,
| | | | | | | | | | | | - Y. Liu
- 1Indiana University School of Medicine, IN,
| | | |
Collapse
|
34
|
Sparano J, Gray R, Goldstein L, Childs B, Brassard D, Bugarini R, Rowley S, Baker J, Shak S, Badve S, Baehner F, Kenny P, Perez E, Shulman L, Martino S, Sledge G, Davidson N. Gene Expression Profiling of Phenotypically-Defined Hormone-Receptor Positive Breast Cancer: Evidence for Increased Transcriptional Activity of the Insulin Growth Factor Receptor Pathway and Other Pathways. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Approximately 70% of all breast cancers are hormone receptor (HR)-positive tumors that are sensitive to endocrine therapy, but some patients have recurrence despite adjuvant endocrine therapy. We performed an exploratory analysis of gene expression in HR-pos operable breast cancer in order to identify potential novel therapeutic targets and biomarkers associated with recurrence. Methods: RNA was extracted from primary tumor samples obtained from 776 patients with stage I-III breast cancer treated with adjuvant chemohormonal therapy in trial E2197 (JCO 2008; 26: 4092-4099), of whom 458 had HR-pos disease (defined in a central lab; JCO 2008; 26: 2473). We evaluated RNA expression patterns (by quantitative RT-PCR using a panel of 371 rationally selected genes) in HR-pos cases compared with the HR-neg cases using weighted T statistics, and determined which genes in the HR-pos, HER2-neg group were associated with recurrence (using Cox proportional hazards model score test, Korn's adjusted P value <5% with false discovery rate < 10%).Results: The top 10 genes exhibiting significantly higher expression in the HR-pos group (p≤ 6.17e-160) included ESR1 plus 5 estrogen regulated genes, confirming our approach of evaluating gene expression in phenotypically-defined subsets. Other pathways that exhibited higher expression in the HR-pos group (among the 40 top genes with higher expression, p<8.66e-53) included the insulin growth factor (IGF) (IRS1, IGFR1, IGFB2), Ras (RhoB, RhoC, RAB27B, GGPS1), and HER pathways (ERBB2, ERBB3, ERBB4), and other genes involved in apoptosis (BCL2, BCL2L1, BAG1, NME6, BBC3), signaling (MAPK3, SEMA3F, RXRA), mismatch repair (MSH3), cell cycle regulation (CCND1), stress response (HSPB1), and tumor suppressor genes (TP53BP1, APC). These patterns were similar in HER2-pos cases. Pathway analysis (Ingenuity) revealed substantial interconnectivity among these genes, especially between IGFR1, ERB2/3/4, MAPK3, BCL2, and CCND1, but not RhoB/RhoC. Genes for which increased expression was associated with increased recurrence included those associated with proliferation (TOP2A, AURKB, PLK1) and apoptosis (BIRC5 - survivin).Conclusions: This exploratory analysis reveals several pathways that exhibit higher transcriptional expression in HR-pos disease, some of which are also associated with a higher risk of recurrence, suggesting that they may be potential therapeutic targets. This provides rationale for testing agents currently available in the clinic that inhibit the IGF and other pathways.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5165.
Collapse
Affiliation(s)
- J. Sparano
- 1Eastern Cooperative Oncology Group, MA,
| | - R. Gray
- 1Eastern Cooperative Oncology Group, MA,
| | | | | | | | | | | | | | | | - S. Badve
- 1Eastern Cooperative Oncology Group, MA,
| | | | - P. Kenny
- 1Eastern Cooperative Oncology Group, MA,
| | - E. Perez
- 4North Central Cancer Treatment Group, MN,
| | | | | | - G. Sledge
- 1Eastern Cooperative Oncology Group, MA,
| | | |
Collapse
|
35
|
Badve S, Shen C, Thorat M, Li L, Gagnon R, Koehler M, Ellis C, O'Shaughnessy J, Baselga J, Sledge G. 5BA Identification of gene expression profiles that predict response to HER2-targeted therapy. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)72035-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
36
|
Baselga J, Gianni L, Gradishar WJ, Hudis C, Perez EA, Piccart-Gebhart M, Schwartzberg LS, Sledge G, Fleming TR. Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e12000] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12000 Sorafenib is a potent multikinase inhibitor approved by the FDA and EMEA for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma. As a single agent, sorafenib has been shown to have activity in pts with BC. Here, we review the TIES program, a compilation of currently ongoing investigator-sponsored phase IIb multinational, randomized, double-blind, placebo-controlled studies that aim to determine the optimal sequencing of pharmacologic agents for the treatment of BC. All studies will combine sorafenib with first- and/or second-line chemotherapy and/or hormonal therapy in pts with HER2-negative metastatic or locally advanced BC, enroll 220 pts, stratify pts by visceral vs nonvisceral disease, allow pts with evaluable and measurable disease, and include pts with treated brain metastases. The primary endpoint of all trials will be progression-free survival. Secondary endpoints will be safety, overall survival, objective response rate, duration of response, and time to progression. Some studies will also assess quality of life, pharmacokinetic sampling, and biomarkers. Additional information on four of the trials is shown below (Table). Patient characteristics and accruals will be reported. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Baselga
- Vall d’ Hebron University Hospital, Barcelona, Spain; Istituto Nazionale Tumori, Milan, Italy; Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Jacksonville, FL; Institut Jules Bordet, Brussels, Belgium; West Clinic, Memphis, TN; University of Indiana, Indianapolis, IN; University of Washington, Seattle, WA
| | - L. Gianni
- Vall d’ Hebron University Hospital, Barcelona, Spain; Istituto Nazionale Tumori, Milan, Italy; Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Jacksonville, FL; Institut Jules Bordet, Brussels, Belgium; West Clinic, Memphis, TN; University of Indiana, Indianapolis, IN; University of Washington, Seattle, WA
| | - W. J. Gradishar
- Vall d’ Hebron University Hospital, Barcelona, Spain; Istituto Nazionale Tumori, Milan, Italy; Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Jacksonville, FL; Institut Jules Bordet, Brussels, Belgium; West Clinic, Memphis, TN; University of Indiana, Indianapolis, IN; University of Washington, Seattle, WA
| | - C. Hudis
- Vall d’ Hebron University Hospital, Barcelona, Spain; Istituto Nazionale Tumori, Milan, Italy; Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Jacksonville, FL; Institut Jules Bordet, Brussels, Belgium; West Clinic, Memphis, TN; University of Indiana, Indianapolis, IN; University of Washington, Seattle, WA
| | - E. A. Perez
- Vall d’ Hebron University Hospital, Barcelona, Spain; Istituto Nazionale Tumori, Milan, Italy; Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Jacksonville, FL; Institut Jules Bordet, Brussels, Belgium; West Clinic, Memphis, TN; University of Indiana, Indianapolis, IN; University of Washington, Seattle, WA
| | - M. Piccart-Gebhart
- Vall d’ Hebron University Hospital, Barcelona, Spain; Istituto Nazionale Tumori, Milan, Italy; Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Jacksonville, FL; Institut Jules Bordet, Brussels, Belgium; West Clinic, Memphis, TN; University of Indiana, Indianapolis, IN; University of Washington, Seattle, WA
| | - L. S. Schwartzberg
- Vall d’ Hebron University Hospital, Barcelona, Spain; Istituto Nazionale Tumori, Milan, Italy; Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Jacksonville, FL; Institut Jules Bordet, Brussels, Belgium; West Clinic, Memphis, TN; University of Indiana, Indianapolis, IN; University of Washington, Seattle, WA
| | - G. Sledge
- Vall d’ Hebron University Hospital, Barcelona, Spain; Istituto Nazionale Tumori, Milan, Italy; Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Jacksonville, FL; Institut Jules Bordet, Brussels, Belgium; West Clinic, Memphis, TN; University of Indiana, Indianapolis, IN; University of Washington, Seattle, WA
| | - T. R. Fleming
- Vall d’ Hebron University Hospital, Barcelona, Spain; Istituto Nazionale Tumori, Milan, Italy; Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; Mayo Clinic, Jacksonville, FL; Institut Jules Bordet, Brussels, Belgium; West Clinic, Memphis, TN; University of Indiana, Indianapolis, IN; University of Washington, Seattle, WA
| |
Collapse
|
37
|
Miller K, Christmon D, Perkins S, Sun J, Schneider B, Storniolo A, Clare S, Ozerdem U, Sledge G. A pilot study of vascular endothelial growth factor inhibition with bevacizumab in patients with lymphedema following breast cancer treatment. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9523 Background: Lymphedema is a significant long-term complication of primary therapy for breast cancer. Anecdotally, several patients (pts) with metastatic disease treated with bevacizumab monotherapy noted improvement in long-standing lymphedema. This pilot study was conducted to explore these observations prospectively. Methods: We used an existing biospecimen bank to conduct a case-control study to compare VEGF-A, -C, -D and VEGFR-3 serum concentrations in breast cancer pts with and without lymphedema (matched for age and LN status). In a separate pilot trial, pts with significant unilateral lymphedema receive bevacizumab, 15 mg/kg every 3 weeks. Baseline assessments include arm volume, interstitial fluid pressure (IFP), extracellular fluid volume by lymphometer (ECF), quality of life (QOL) and plasma VEGF-C, -D, and R3. IFP is measured serially for 24 hours after the first treatment; arm volume, ECF, QOL, and plasma VEGF-C/D/R3 are assessed at 3 and 6 weeks. Results: Samples were available for 16 pts with chronic lymphedema and 31 matched controls. Median VEGF-C levels were significantly increased in pts with lymphedema (6895 pg/ml vs. 5349 pg/ml, p=0.001). Twelve pts have been enrolled in the pilot trial. Median duration of lymphedema was 6.3 years (0.5–16.6) Median time since surgery was 5.5 years (1.9–17.6); median time since radiation (n=10) was 5.1 years (1.3–8.3). Complete IFP data is available in 9 pts. Baseline IFP was significantly higher in the affected compared to unaffected arm (7.63 vs. -0.87 mmHg; p=0.0023). Mean IFP in the affected arm decreased an average of 41.9% 24 hours after bevacizumab infusion (7.63 vs. 4.88 mmHg; p=0.07). ECF, VEGF-1, and VEGF-R3 levels all significantly decreased three weeks after initial treatment. Two patients met the definition of response with a ≥ 25% reduction in excess arm volume though the mean difference in excess arm volume did not significantly change (p=0.19). Conclusions: Preliminary data supports the hypothesis that VEGF plays a central role in the development and persistence of lymphedema after local therapy for breast cancer. Bevacizumab acutely decreases IFP, leading to a decrease in ECF and modest improvement in arm volume. [Table: see text]
Collapse
Affiliation(s)
- K. Miller
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; LaJolla Institute of Molecular Medicine, La Jolla, CA
| | - D. Christmon
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; LaJolla Institute of Molecular Medicine, La Jolla, CA
| | - S. Perkins
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; LaJolla Institute of Molecular Medicine, La Jolla, CA
| | - J. Sun
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; LaJolla Institute of Molecular Medicine, La Jolla, CA
| | - B. Schneider
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; LaJolla Institute of Molecular Medicine, La Jolla, CA
| | - A. Storniolo
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; LaJolla Institute of Molecular Medicine, La Jolla, CA
| | - S. Clare
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; LaJolla Institute of Molecular Medicine, La Jolla, CA
| | - U. Ozerdem
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; LaJolla Institute of Molecular Medicine, La Jolla, CA
| | - G. Sledge
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; LaJolla Institute of Molecular Medicine, La Jolla, CA
| |
Collapse
|
38
|
Carlson RW, O'Neill A, Vidaurre T, Gomez HL, Badve S, Sledge G. Randomized phase II trial of gefitinib plus anastrozole or fulvestrant in postmenopausal, metastatic breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1013] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1013 Background: Preclinical data documents interactions between the signal transduction pathways for ER and for EGFR, and these interactions may relate to endocrine resistance in ER+ breast cancer. Limited clinical data is available. Methods: This multi-institutional, single-stage, non-comparative, randomized phase II study tested the EGFR tyrosine kinase inhibitor gefitinib 250 mg daily PO plus endocrine therapy with either anastrozole 1 mg/day PO (AG Arm) versus fulvestrant 250 mg IM every 4-weeks (FG Arm). Eligible pts were postmenopausal women with ER+ and/or PgR+ measurable metastatic breast cancer with no prior endocrine therapy for metastatic disease, no prior adjuvant AI or fulvestrant, no more than two chemotherapy regimens for metastatic disease, ECOG status 0–2, no CNS metastasis, and adequate bone marrow, liver, and renal function. Primary endpoint was RECIST determined clinical benefit (CR+PR+SD for ≥6 mos) and secondary endpoints were toxicity and interaction of biomarkers with clinical benefit. Results: 148 pts were registered, and 142 pts are eligible and analyzable, 73 to AG and 69 to FG. Treatment groups were balanced for race, age, ECOG status, and sites of disease. Median follow-up is 35 mos. Median N of 4-week cycles of treatment is 6 (range 1–42) in both groups. Treatment was terminated for disease progression in 74% v 75%, toxicity 7% v 10%, death 1% v 3%, withdrawal 8% v 1%, and other 3% v 7% in the AG v FG arms, respectively. Clinical benefit rate (95% CI) is 42% (30%-53%) v 38% (28%-52%) for AG v FG, respectively. Response rates are CR 3% v 4%, PR 21% v 17%, SD for ≥6 mos 18% v 17% for AG v FG. Median PFS is 5.7 mos v 5.2 mos and median OS is 30.2 mos v 23.8 mos for AG v FG, respectively. Overall worst toxicity grade experienced for AG is G1 and 2 = 62%; G3 = 28%; G4 = 4%, G5 = 3%; for FG was G1 and 2 = 58%; G3 = 27%; G4 = 7%; G5 = 4%. G3 + G4 + G5 toxicities occurring in ≥5% of either treatment are diarrhea (5% v 13%), SGOT elevation (7% v 8%), and infection without neutropenia (1% v 6%) for AG v FG. Conclusions: Both anastrozle and fulvestrant are active endocrine agents in combination with gefitinib and both are generally well tolerated. Anastrozole plus gefitinib appears to be the better combination to take forward for phase III comparisons. [Table: see text]
Collapse
Affiliation(s)
- R. W. Carlson
- Stanford University, Stanford, CA; Dana-Farber Cancer Institute, Boston, MA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Indiana University Cancer Center, Indianapolis, IN
| | - A. O'Neill
- Stanford University, Stanford, CA; Dana-Farber Cancer Institute, Boston, MA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Indiana University Cancer Center, Indianapolis, IN
| | - T. Vidaurre
- Stanford University, Stanford, CA; Dana-Farber Cancer Institute, Boston, MA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Indiana University Cancer Center, Indianapolis, IN
| | - H. L. Gomez
- Stanford University, Stanford, CA; Dana-Farber Cancer Institute, Boston, MA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Indiana University Cancer Center, Indianapolis, IN
| | - S. Badve
- Stanford University, Stanford, CA; Dana-Farber Cancer Institute, Boston, MA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Indiana University Cancer Center, Indianapolis, IN
| | - G. Sledge
- Stanford University, Stanford, CA; Dana-Farber Cancer Institute, Boston, MA; Instituto de Enfermedades Neoplasicas, Lima, Peru; Indiana University Cancer Center, Indianapolis, IN
| |
Collapse
|
39
|
Miller KD, Christmon D, Schneider BP, Storniolo A, Clare SE, Sledge GW. A pilot study of vascular endothelial growth factor inhibition with bevacizumab in patients with lymphedema following breast cancer treatment. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-6142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #6142
Purpose: Lymphedema is a significant long-term complication of primary therapy for breast cancer but little is known regarding its etiology and persistence other than relation to the number of lymph nodes (LN) removed. We suggest the following model: Mechanical disruption of normal lymphatic drainage leads to increased back pressure on lymphatic vessels producing an increase in interstitial fluid pressure (IFP). The increased in IFP triggers local production of VEGF-C to stimulate compensatory lymphangiogenesis. As VEGF-A (and to a lesser extent –C) also increases vascular permeability, the consequent increase in interstitial fluid and edema predominate. Anecdotally, several patients (pts) with metastatic disease treated with bevacizumab monotherapy noted improvement in long-standing lymphedema. This pilot study was conducted to explore these observations prospectively.
 Methods: We used an existing biospecimen bank to conduct a case-control study to compare VEGF-A, -C, -D and VEGFR-3 serum concentrations in breast cancer pts with and without lymphedema (matched for age and LN status). In a separate pilot trial, pts with significant unilateral lymphedema receive bevacizumab, 15 mg/kg every 3 weeks. Baseline assessments include arm volume, interstitial fluid pressure (IFP), extracellular fluid volume by lymphometer (ECF), quality of life (QOL) and plasma VEGF-C, -D, and R-3. IFP is measured serially for 24 hours after the first treatment; arm volume, ECF, QOL, and plasma VEGF-C/D/R-3 are assessed at 3 and 6 weeks.
 Results: Samples were available for 16 pts with chronic lymphedema and 24 matched controls. Median VEGF-C levels were significantly increased in pts with lymphedema (6895 pg/ml vs. 5349 pg/ml, p=0.001). Median VEGF-A levels were slightly higher in pts with lymphedema (375 pg/ml vs.250 pg/ml, p=NS). Eight pts have been enrolled in the pilot trial thus far. Median duration of lymphedema was 4.4 years (2.2-16.6) Median time since surgery was 7.1 years (3.4-17.6); median time since radiation (n=7) was 4.4 years (2.3-7.9). Complete IFP data is available in 5 pts. Baseline IFP was significantly higher in the affected compared to unaffected arm (9.04 vs. -2.07 mmHg; p=0.0017). Median IFP in the affected arm decreased an average of 42.6% 24 hours after bevacizumab infusion (11.1 vs. 6.9 mmHg; p=0.09). Total arm circumference decreased by an average of 2.8 cm three weeks after initial treatment.
 Conclusions: Preliminary data supports the hypothesis that VEGF plays a central role in the development and persistence of lymphedema after local therapy for breast cancer. Inhibiting VEGF acutely decreases IFP and may be an effective treatment. Treatment and accrual to the pilot trial continues; full data will be available by December 2008.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6142.
Collapse
Affiliation(s)
- KD Miller
- 1 Division of Hematology and Oncology, Indiana University, Indianapolis, IN
| | - D Christmon
- 1 Division of Hematology and Oncology, Indiana University, Indianapolis, IN
| | - BP Schneider
- 1 Division of Hematology and Oncology, Indiana University, Indianapolis, IN
| | - A Storniolo
- 1 Division of Hematology and Oncology, Indiana University, Indianapolis, IN
| | - SE Clare
- 2 Surgery, Indiana University, Indianapolis, IN
| | - GW Sledge
- 1 Division of Hematology and Oncology, Indiana University, Indianapolis, IN
| |
Collapse
|
40
|
Duchnowska R, Jassem J, Shen C, Thorat M, Li L, Morimiya A, Zhao Q, Biernat W, Mandat T, Staszkiewicz R, Och W, Szostak W, Gugala K, Trojanowski T, Czartoryska-Arlukowicz B, Szczylik C, Nakshatri H, Steeg P, Sledge G, Badve S. Molecular characteristics of matched brain metastasis (BM) versus the primary breast cancer (PBC). Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-2028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #2028
Background: Brain is increasingly a site of relapse in breast cancer patients, however the molecular patho-physiology of this process is not well understood. Using a novel assay allowing high-throughput analysis of gene expression from formalin-fixed paraffin-embedded (FFPET) tumor samples, we compared molecular characteristics of BM with those of the PBC in a series of breast cancer patients who underwent excision of brain metastasis.
 Methods: In each patient we performed molecular analysis of paired archived FFPET specimens from both the PBC and excised BM. Of the 37 pairs of PBC/BM samples, 24 pairs had sufficient pathology material for molecular analysis. Patient characteristics: mean age at PBC diagnosis was 46.7 years (range 27-67 years); 7 (29%) ER+, 17 (71%) ER-, 12 (50%) HER2-positive(3+). We performed cDNA-mediated annealing, selection, extension and ligation (DASL) assay (Illumina Corp) for expression of 502 known cancer genes, using 200 ng RNA. Statistical analysis for microarrays (SAM) accounting for the pairing of the primary and metastasized tumors was used to identify differentially expressed genes while controlling the false discovery rate (FDR <0.01). BeadStudio™ Absolute correlation clustering was used to cluster samples based on their expression profiles.
 Results: In only 7 (29%) cases matched PBC and BM pair clustered together on unsupervised hierarchical clustering, the pairs in remaining cases clustered apart. Comparison of the two groups (PBC and BM) showed that 41 genes were up regulated in BM, including proliferation genes (CDC2, CDC25a, CCNA2 and E2F family), anti-apoptotic (BIRC5), DNA repair (RAD51, -54b, XRCC2, BRCA2, BARD1, TOP1), angiogenesis (VEGF), and development of drug resistance (ABCB1, -G2). In contrast, the 43 genes that were down regulated in BM included those associated with invasion (MMP2, -3, -14), cellular motility, and epithelial to mesenchymal transformation (CDH11). Additional analysis to validate these trends and to identify potential therapeutic targets is underway.
 Conclusions: Although some BM retain remarkable similarity to the PBC, majority exhibit considerable deviation in their gene expression profile. These “adaptive” changes include greater resistance to drug therapy, increased DNA repair, a reversal back to the epithelial phenotype and decreased capacity for cell motility and invasion.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2028.
Collapse
Affiliation(s)
- R Duchnowska
- 1 Military Institute of Medicine, Warsaw, Poland
| | - J Jassem
- 2 Medical University, Gdansk, Poland
| | - C Shen
- 2 Medical University, Gdansk, Poland
| | - M Thorat
- 3 Indiana University, Indianapolis
| | - L Li
- 3 Indiana University, Indianapolis
| | | | - Q Zhao
- 3 Indiana University, Indianapolis
| | - W Biernat
- 2 Medical University, Gdansk, Poland
| | - T Mandat
- 1 Military Institute of Medicine, Warsaw, Poland
| | | | - W Och
- 4 General Hospital, Olsztyn, Poland
| | | | - K Gugala
- 4 General Hospital, Olsztyn, Poland
| | | | | | - C Szczylik
- 1 Military Institute of Medicine, Warsaw, Poland
| | | | - P Steeg
- 7 National Cancer Institute, Bethesda
| | - G Sledge
- 3 Indiana University, Indianapolis
| | - S Badve
- 3 Indiana University, Indianapolis
| |
Collapse
|
41
|
O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, Koehler M, Laabs S, Florance A, Roychowdhury D. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1015] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
Matei D, Kelich S, Cao L, Menning N, Emerson R, Emerson R, Rao J, Sledge G. Induction of VEGF secretion in ovarian cancer by PDGF BB. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5557 Background: We identified the PDGFR as a potential target in epithelial ovarian carcinoma (EOC). This led us to test whether inhibition of the receptor affects ovarian cancer cell proliferation and survival and regulates other processes critical to tumor growth and metastasis. We postulated that the PDGF-PDGFR axis regulates VEGF secretion in EOC. Methods: VEGF secretion in ovarian tumors, cancer cells, serum and ascites was measured by IHC, Western Blot and ELISA. The HOG Gyn03–62 protocol was a phase II protocol for patients with recurrent platinum resistant EOC. Patients were treated with imatinib and docetaxel. Serum and tumor samples from patients enrolled on this protocol were analyzed for VEGF. Results: VEGF expression was quantified by IHC in ovarian tumors. Of 21 PDGFR expressing ovarian tumors, seven specimens immunostained strongly for VEGF and six tumors demonstrated 2+ VEGF reactive extracellular (secreted) material. PDGF and VEGF secretion was measured in 17 specimens of malignant EOC ascites. The levels of PDGF BB and VEGF were strongly correlated (Pearson coefficient =0.728, p-value=0.001), suggesting that the two pathways interconnect. There was no correlation between PDGF AA and VEGF levels. VEGF levels were measured in 13 paired serum samples from patients enrolled in the clinical protocol HOG: Gyn03–62, before and after treatment. VEGF serum levels were stabilized or decreased in 9 of 13 EOC patients treated with imatinib. In conditioned media from primary cells, VEGF secretion was four fold higher for tumor derived cells than for cells derived from the normal ovarian epithelium. PDGF increased ten-fold VEGF secretion in PDGFR expressing immortalized ovarian cells (C272/hTert/E7 and C889/hTert), while imatinib reduced VEGF production to basal state. The effects of imatinib were mediated via inhibition of Akt and MAPK pathways, by stabilization of HIF1 alpha. In ovarian cancer cells overexpressing consitutively active Akt, imatinib inhibited only partially the secretion of VEGF compared to control cells, suggesting that the PI3K/Akt pathway is significantly implicated in PDGF-stimulated VEGF secretion. Conclusions: These results suggest that by blocking the PDGFR, imatinib inhibits VEGF production. This affects the tumor microenvironment favoring ovarian tumor growth and metastasis. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Matei
- Indiana Univ, Indianapolis, IN; UCLA, Los Angeles, CA
| | - S. Kelich
- Indiana Univ, Indianapolis, IN; UCLA, Los Angeles, CA
| | - L. Cao
- Indiana Univ, Indianapolis, IN; UCLA, Los Angeles, CA
| | - N. Menning
- Indiana Univ, Indianapolis, IN; UCLA, Los Angeles, CA
| | - R. Emerson
- Indiana Univ, Indianapolis, IN; UCLA, Los Angeles, CA
| | - R. Emerson
- Indiana Univ, Indianapolis, IN; UCLA, Los Angeles, CA
| | - J. Rao
- Indiana Univ, Indianapolis, IN; UCLA, Los Angeles, CA
| | - G. Sledge
- Indiana Univ, Indianapolis, IN; UCLA, Los Angeles, CA
| |
Collapse
|
43
|
Abstract
1013 Background: C alone has good activity and tolerability in metastatic breast cancer (MBC) and when combined with docetaxel improves response and survival. C combined with B in heavily pretreated MBC improved the response rate but not PFS. In untreated MBC, the addition of B to chemotherapy significantly improves progression-free survival (PFS) which suggests that B, is most effective in early disease. Methods: Primary objective of this single-arm, 2-phase study, is to evaluate PFS in MBC patients receiving first-line treatment with C 1,000 mg/m2 twice daily on days 1–15 (28 doses) and B 15 mg/kg on day 1. Treatment was repeated every 21 days until progression. Eligibility criteria included HER2-negative MBC previously untreated for metastatic disease; ECOG performance status =1; no prior anti-angiogenic or oral fluoropyrimidine therapy. A sample size of 109 patients (including dropouts) was required to give 90% power to test an improvement from 4 months median PFS to 5.6 months with the two-sided test (a 5%) Results: At data cut-off, 103 patients had received study medication. Present results are based on 103 patients (ITT population), except tumor response which is based on 91 patients who had response evaluation. The average # of cycles received in first phase is 6.8. 84 pts.are alive at this time. 38.5% (35/91) pts. have had a response: complete response 5.5%; partial response 33.0%. Stable disease is 42.9% with 81.4% clinical benefit. Planned dose received is 77.7 % for C and 99.0 % for B. The majority of adverse events (AEs) were mild or moderate. The most common grade 3 AEs were hand-foot syndrome (13%) and pain (10%); grade 4 pulmonary embolism occurred in 2% in the first phase of the study. Conclusions: Updated results with longer follow-up including toxicity, TTP and PFS will be presented at the meeting. It appears that in first-line C+B is active for MBC and is well tolerated, with few grade 3/4 toxicities. [Table: see text]
Collapse
Affiliation(s)
- G. Sledge
- Indiana University, Indianapolis, IN; Roche Laboratories Inc., Nutley, NJ; Northwestern University, Chicago, IL
| | - K. Miller
- Indiana University, Indianapolis, IN; Roche Laboratories Inc., Nutley, NJ; Northwestern University, Chicago, IL
| | - C. Moisa
- Indiana University, Indianapolis, IN; Roche Laboratories Inc., Nutley, NJ; Northwestern University, Chicago, IL
| | - W. Gradishar
- Indiana University, Indianapolis, IN; Roche Laboratories Inc., Nutley, NJ; Northwestern University, Chicago, IL
| |
Collapse
|
44
|
Wang M, Gradishar WJ, Sparano JA, Perez EA, Sledge G. A phase II trial of capecitabine (C) in combination with the farnesyltransferase (FT) inhibitor (FTI), tipifarnib (T), in patients (pt) with metastatic breast cancer (MBC): ECOG trial 1103. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1036 Background: Approximately 30% of human cancers have mutated Ras genes that produce proteins that remain in an active state causing uncontrolled proliferative signals. Post-translational modification of Ras include farneyslation catalyzed by FT. Tipifarnib (R115777) is an oral FTI active against human tumor cell lines and exhibiting modest single agent activity in pts with previously treated MBC. A previous phase I trial reported that CT inhibited farneyslation in peripheral blood mononuclear cells without affecting the pharmacokinetics of either agent. Objective: To evaluate objective response rate (ORR) of CT in taxane refractory MBC and to secondarily evaluate associated toxicity and progression-free survival (PFS). Methods: Pt with measurable MBC, previously treated (rx) with an anthracycline and relapse on a taxane or within 30 days (d). Study rx: T- 300 mg, po BID × 14 d plus C- 1,000 mg/m2, po BID × 14 d, followed by 7 d rest. Tumor reassessment was repeated q 3 cycles. The study was designed to detect improvement in ORR from 25% with C alone to 40% for the CT combination (90.5% power; type I error rate of 9.9%; 21 responses in 64 eligible pt needed to be promising. Results: 66/71 pt are available for primary analysis. Median age 50 yrs. Performance status: 0–1, 100%. ORR: PR-4.8% (3/62) [95% CI 0.01, 0.13], SD - 21% (13/62) [ 95% CI 0.12, 0.33]. Median survival - 10.6 months. Toxicity (%): anemia - 8(G3/4), neutropenia - 30 (G3/4), thrombocytopenia - 8 (G3/4), HFS-8 (G3), nausea/vomiting - 11(G3), diarrhea - 8 (G3), sensory neuropathy - 5 (G3). Conclusion: CT in taxane -refractory MBC has low antitumor activity without excessive toxicity. More mature data, including PFS, will be presented. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Wang
- Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; Montefiore Hosp, New York, NY; Mayo Clinic, Jacksonville, FL; Indiana U., Indianapolis, IN
| | - W. J. Gradishar
- Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; Montefiore Hosp, New York, NY; Mayo Clinic, Jacksonville, FL; Indiana U., Indianapolis, IN
| | - J. A. Sparano
- Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; Montefiore Hosp, New York, NY; Mayo Clinic, Jacksonville, FL; Indiana U., Indianapolis, IN
| | - E. A. Perez
- Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; Montefiore Hosp, New York, NY; Mayo Clinic, Jacksonville, FL; Indiana U., Indianapolis, IN
| | - G. Sledge
- Dana-Farber Cancer Institute, Boston, MA; Northwestern University, Chicago, IL; Montefiore Hosp, New York, NY; Mayo Clinic, Jacksonville, FL; Indiana U., Indianapolis, IN
| |
Collapse
|
45
|
Moulder SL, O’Neill A, Arteaga C, Pins M, Sparano J, Sledge G, Davidson N. Final Results of ECOG1100: A phase I/II study of combined blockade of the ErbB receptor network in patients with HER2- overexpressing metastatic breast cancer (MBC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1033 Background: Activation of EGF receptor has been associated with resistance to trastuzumab in breast cancer cell lines. EGFR tyrosine kinase inhibitors inhibit HER2 phosphorylation and synergize with trastuzumab in HER2+ cell lines that co-express EGFR. Methods: Pts with MBC and HER2 overexpression by immunohistochemistry (3+) and/or HER2 gene-amplification by FISH, 0–2 prior chemotherapy regimens for met disease, LVEF 50%, and no prior trastuzumab were treated with trastuzumab 2 mg/kg/wk and gefitinib 250- 500 mg/day until disease progression, unacceptable toxicity or withdrawal of consent. The phase I portion of the trial used a 3+3 design to determine MTD. In the phase II portion of the trial, patients were stratified based upon prior chemotherapy exposure (Group 1= no prior exposure to chemotherapy, Group 2= prior exposure to 1–2 chemotherapy regimens). Response measured using RECIST criteria. The primary endpoint was to increase proportion progression free from 50 to 65% at 6 months in Group 1 and from 50 to 70% at 3 months in Group 2. Results: Phase I: DLT (Grade 3 diarrhea) occurred in 2/3 patients treated at the 500 mg/day dose level of gefitinib in combination with weekly trastuzumab. 0/3 patients treated at the 250 mg/day dose level experienced DLT. This was considered MTD and was the dose selected for the Phase II portion of the trial. Phase II: 36 eligible pts were enrolled. Most patients were ECOG PS of 0 and had visceral organ involvement. Of the patients enrolled in Group 1, one pt achieved a CR, one PR and 7 had SD (≥ 24 weeks). Median time to progression (TTP) was 2.9 months (95% CI, 2.5–4). In Group 2 no responses were observed with a median TTP of 2.5 months (95% CI, 1.5- 2.7). Most common severe toxicities were rash (grade 3, 14%) and diarrhea (grade 3, 30%). No grade 3 cardiac toxicity was encountered. Conclusions: Trastuzumab in combination with gefitinib at doses of 250 mg/day demonstrated an acceptable toxicity profile; however, during planned interim analysis, the TTP did not meet predetermined statistical endpoints required for study continuation. These results do not support the further use of this combination and have implications for other trials using trastuzumab and EGFR TK inhibitors simultaneously. [Table: see text]
Collapse
Affiliation(s)
- S. L. Moulder
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - A. O’Neill
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - C. Arteaga
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - M. Pins
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - J. Sparano
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - G. Sledge
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| | - N. Davidson
- MD Anderson Cancer Ctr, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University Medical Center, Nashville, TN; Northwestern University, Chicago, IL; Montefiore Medical Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; John Hopkins University, Baltimore, MD; Eastern Cooperative Oncology Group
| |
Collapse
|
46
|
Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan X, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes DF. Re: p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2007; 99:738. [PMID: 17470742 PMCID: PMC7717107 DOI: 10.1093/jnci/djk163] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- PL Porter
- Fred Hutchinson Cancer Research Center, Seattle WA
- University of Washington, Seattle WA
- Address for editorial correspondence: Peggy L. Porter, M.D., Member, Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N, Seattle, WA 98109, PH: 206-667-3751; FAX: 206-667-5815,
| | - WE Barlow
- University of Washington, Seattle WA
- SWOG Statistical Center, Seattle WA
| | - I-T Yeh
- University of Texas Health Science Center, San Antonio, TX
| | - M-G Lin
- Fred Hutchinson Cancer Research Center, Seattle WA
| | - X Yuan
- Fred Hutchinson Cancer Research Center, Seattle WA
| | - E Donato
- Fred Hutchinson Cancer Research Center, Seattle WA
| | - GW Sledge
- Indiana University, Indianapolis, IN
| | | | | | - CM Haskell
- University of California, Los Angeles CA
| | | | - JM Roberts
- Fred Hutchinson Cancer Research Center, Seattle WA
| | | | - DF Hayes
- University of Michigan, Ann Arbor MI
| |
Collapse
|
47
|
|
48
|
Piccart M, Burzykowski T, Buyse M, Nabholtz J, Carmichael J, Lück H, Sledge G, Paridaens R, Biganzoli L, Therasse P. Meta-analysis of taxanes alone or in combination with anthracyclines versus non taxane-based regimens as first-line therapy of patients with metastatic breast cancer (MBC): a lesson from the past and a message for the future. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80454-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
49
|
de la Garza Salazar J, Içli F, Pienkowski T, Aapro M, Hortobagyi G, Martin M, Piccart M, Sledge G, Pritchard K, Albain K. ABREAST: A new global registry of adjuvant strategies in patients with early stage breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. de la Garza Salazar
- INCan Mexico, Mexico City, Mexico; Ibni Sina Hosp, Ankara, Turkey; Maria Sklodowska-Curie Memorial Cancer Ctr, Warsaw, Poland; Clin de Genolier, Genolier, Switzerland; UT MD Anderson Cancer Ctr, Houston, TX; Hosp Clin San Carlos, Madrid, Spain; Inst Jules Bordet, Brussels, Belgium; Indiana Univ Medcl Ctr, Indianapolis, IN; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Lolola Univ Medcl Ctr, Maywood, IL
| | - F. Içli
- INCan Mexico, Mexico City, Mexico; Ibni Sina Hosp, Ankara, Turkey; Maria Sklodowska-Curie Memorial Cancer Ctr, Warsaw, Poland; Clin de Genolier, Genolier, Switzerland; UT MD Anderson Cancer Ctr, Houston, TX; Hosp Clin San Carlos, Madrid, Spain; Inst Jules Bordet, Brussels, Belgium; Indiana Univ Medcl Ctr, Indianapolis, IN; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Lolola Univ Medcl Ctr, Maywood, IL
| | - T. Pienkowski
- INCan Mexico, Mexico City, Mexico; Ibni Sina Hosp, Ankara, Turkey; Maria Sklodowska-Curie Memorial Cancer Ctr, Warsaw, Poland; Clin de Genolier, Genolier, Switzerland; UT MD Anderson Cancer Ctr, Houston, TX; Hosp Clin San Carlos, Madrid, Spain; Inst Jules Bordet, Brussels, Belgium; Indiana Univ Medcl Ctr, Indianapolis, IN; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Lolola Univ Medcl Ctr, Maywood, IL
| | - M. Aapro
- INCan Mexico, Mexico City, Mexico; Ibni Sina Hosp, Ankara, Turkey; Maria Sklodowska-Curie Memorial Cancer Ctr, Warsaw, Poland; Clin de Genolier, Genolier, Switzerland; UT MD Anderson Cancer Ctr, Houston, TX; Hosp Clin San Carlos, Madrid, Spain; Inst Jules Bordet, Brussels, Belgium; Indiana Univ Medcl Ctr, Indianapolis, IN; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Lolola Univ Medcl Ctr, Maywood, IL
| | - G. Hortobagyi
- INCan Mexico, Mexico City, Mexico; Ibni Sina Hosp, Ankara, Turkey; Maria Sklodowska-Curie Memorial Cancer Ctr, Warsaw, Poland; Clin de Genolier, Genolier, Switzerland; UT MD Anderson Cancer Ctr, Houston, TX; Hosp Clin San Carlos, Madrid, Spain; Inst Jules Bordet, Brussels, Belgium; Indiana Univ Medcl Ctr, Indianapolis, IN; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Lolola Univ Medcl Ctr, Maywood, IL
| | - M. Martin
- INCan Mexico, Mexico City, Mexico; Ibni Sina Hosp, Ankara, Turkey; Maria Sklodowska-Curie Memorial Cancer Ctr, Warsaw, Poland; Clin de Genolier, Genolier, Switzerland; UT MD Anderson Cancer Ctr, Houston, TX; Hosp Clin San Carlos, Madrid, Spain; Inst Jules Bordet, Brussels, Belgium; Indiana Univ Medcl Ctr, Indianapolis, IN; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Lolola Univ Medcl Ctr, Maywood, IL
| | - M. Piccart
- INCan Mexico, Mexico City, Mexico; Ibni Sina Hosp, Ankara, Turkey; Maria Sklodowska-Curie Memorial Cancer Ctr, Warsaw, Poland; Clin de Genolier, Genolier, Switzerland; UT MD Anderson Cancer Ctr, Houston, TX; Hosp Clin San Carlos, Madrid, Spain; Inst Jules Bordet, Brussels, Belgium; Indiana Univ Medcl Ctr, Indianapolis, IN; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Lolola Univ Medcl Ctr, Maywood, IL
| | - G. Sledge
- INCan Mexico, Mexico City, Mexico; Ibni Sina Hosp, Ankara, Turkey; Maria Sklodowska-Curie Memorial Cancer Ctr, Warsaw, Poland; Clin de Genolier, Genolier, Switzerland; UT MD Anderson Cancer Ctr, Houston, TX; Hosp Clin San Carlos, Madrid, Spain; Inst Jules Bordet, Brussels, Belgium; Indiana Univ Medcl Ctr, Indianapolis, IN; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Lolola Univ Medcl Ctr, Maywood, IL
| | - K. Pritchard
- INCan Mexico, Mexico City, Mexico; Ibni Sina Hosp, Ankara, Turkey; Maria Sklodowska-Curie Memorial Cancer Ctr, Warsaw, Poland; Clin de Genolier, Genolier, Switzerland; UT MD Anderson Cancer Ctr, Houston, TX; Hosp Clin San Carlos, Madrid, Spain; Inst Jules Bordet, Brussels, Belgium; Indiana Univ Medcl Ctr, Indianapolis, IN; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Lolola Univ Medcl Ctr, Maywood, IL
| | - K. Albain
- INCan Mexico, Mexico City, Mexico; Ibni Sina Hosp, Ankara, Turkey; Maria Sklodowska-Curie Memorial Cancer Ctr, Warsaw, Poland; Clin de Genolier, Genolier, Switzerland; UT MD Anderson Cancer Ctr, Houston, TX; Hosp Clin San Carlos, Madrid, Spain; Inst Jules Bordet, Brussels, Belgium; Indiana Univ Medcl Ctr, Indianapolis, IN; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Lolola Univ Medcl Ctr, Maywood, IL
| |
Collapse
|
50
|
Shafqat A, Einhorn LH, Hanna N, Sledge GW, Hanna A, Juliar BE, Monahan P, Bhatia S. Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Ann Oncol 2005; 16:1545-50. [PMID: 15919683 DOI: 10.1093/annonc/mdi267] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND To understand the pathogenesis of fatigue in cancer, we conducted a cross-sectional study using Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-Fatigue (FACT-F) instruments to measure fatigue and assessed laboratory studies. PATIENTS AND METHODS 174 patients with cancer, who had undergone treatment within the last six months, answered the questionnaires and the Brief Version Zung Self-Rating Depression Scale (BZSDS). Blood samples were drawn for hemoglobin, albumin, thyroid stimulating hormone (TSH), dehydroepiandrosterone-sulfate (DHEAS) and tumor necrosis factor-alpha (TNF- alpha). Testosterone levels were checked in male patients. RESULTS Clinically significant fatigue with BFI > or =4 was present in 52.0% of patients. Measurement of laboratory parameters revealed the following: DHEAS levels <80 mcg/dl in males and <36 mcg/dl in females=54.1%; BZSDS scores > or =27=20.1%; testosterone levels <200 ng/dl=26.4% of male patients. Significant correlations were noted between BFI and FACT-F, albumin levels, hemoglobin levels and BZSDS scores. In addition, for male patients BFI correlated with DHEAS and testosterone levels. In multiple linear regression, hemoglobin, BZSDS scores and current opioid use were associated with response BFI. For male patients, DHEAS <80 mcg/dl, increased BZSDS and testosterone <200 ng/dl were associated with increased BFI. CONCLUSION Fatigue is common in this population and BFI correlates with more extensive measurements. Abnormalities such as decreased testosterone and DHEAS may lead to interventions that can be therapeutically exploited.
Collapse
Affiliation(s)
- A Shafqat
- Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | | | | | | | | | | | | | | |
Collapse
|